<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Microb Pathog</journal-id><journal-id journal-id-type="iso-abbrev">Microb. Pathog</journal-id><journal-title-group><journal-title>Microbial Pathogenesis</journal-title></journal-title-group><issn pub-type="ppub">0882-4010</issn><issn pub-type="epub">1096-1208</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">S0882-4010(20)30528-3</article-id><article-id pub-id-type="doi">10.1016/j.micpath.2020.104241</article-id><article-id pub-id-type="publisher-id">104241</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Khodadadi</surname><given-names>Ehsaneh</given-names></name><email>ehsaneh.khodadadi@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Maroufi</surname><given-names>Parham</given-names></name><email>Dr.parhammaroufi@yahoo.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Khodadadi</surname><given-names>Ehsan</given-names></name><email>E.khodadadi@yahoo.com</email><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Esposito</surname><given-names>Isabella</given-names></name><email>Isabellaesposito@libero.it</email><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Ganbarov</surname><given-names>Khudaverdi</given-names></name><email>Khuda1949@mail.ru</email><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Espsoito</surname><given-names>Silvano</given-names></name><email>silvanoesposito@libero.it</email><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Yousefi</surname><given-names>Mehdi</given-names></name><email>yousefime@tbzmed.ac.ir</email><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Zeinalzadeh</surname><given-names>Elham</given-names></name><email>Elham_leyenda@yahoo.com</email><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Kafil</surname><given-names>Hossein Samadi</given-names></name><email>Kafilhs@tbzmed.ac.ir</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff2"><label>b</label>Department of Orthopedy, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff3"><label>c</label>Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran</aff><aff id="aff4"><label>d</label>Department of Medicine, University of Salerno, Italy</aff><aff id="aff5"><label>e</label>Department of Microbiology, Baku State University, Baku, Azerbaijan</aff><aff id="aff6"><label>f</label>Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff7"><label>g</label>Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 5166614711, Iran. <email>Kafilhs@tbzmed.ac.ir</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>5</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>5</day><month>5</month><year>2020</year></pub-date><volume>146</volume><fpage>104241</fpage><lpage>104241</lpage><history><date date-type="received"><day>4</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>28</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>29</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>The recent epidemic outbreak of a novel human coronavirus called SARS-CoV-2 and causing the respiratory tract disease COVID-19 has reached worldwide resonance and a global effort is being undertaken to characterize the molecular features and evolutionary origins of this virus. Therefore, rapid and accurate identification of pathogenic viruses plays a vital role in selecting appropriate treatments, saving people's lives and preventing epidemics. Additionally, general treatments, coronavirus-specific treatments, and antiviral treatments useful in fighting COVID-19 are addressed. This review sets out to shed light on the SARS-CoV-2 and host receptor recognition, a crucial factor for successful virus infection and taking immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein of SARS-CoV-2. A variety of improved or new approaches also have been developed. It is anticipated that this will assist researchers and clinicians in developing better techniques for timely and effective detection of coronavirus infection. Moreover, the genomic sequence of the virus responsible for COVID-19, as well as the experimentally determined three-dimensional structure of the Main protease (Mpro) is available. The reported structure of the target Mpro was described in this review to identify potential drugs for COVID-19 using virtual high throughput screening.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">COVID-19 is a highly infectious disease associated with high mortality.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Rapid and accurate identification of viruses plays a vital role in selecting appropriate treatments.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">The reported structure of the target Mpro was described in this review to identify potential drugs.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Using virtual high throughput screening will help to identify potential drugs.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Coronavirus</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>Epitopes</kwd><kwd>Immune-informatics</kwd></kwd-group><kwd-group id="kwrds0015"><title>Abbreviations</title><kwd>COVID-19, Coronavirus disease 2019</kwd><kwd>ssRNA, single-stranded RNA</kwd><kwd>MERS-CoV, Middle East respiratory syndrome coronavirus</kwd><kwd>SARS-CoV, severe acute respiratory syndrome coronavirus</kwd><kwd>BtCoV, bat coronavirus</kwd><kwd>nsp, non-structural proteins</kwd><kwd>ADE, antibody-dependent enhancement</kwd><kwd>RNP, ribonucleoprotein</kwd><kwd>NTD, N-terminal RNA-binding domain</kwd><kwd>CTD, C-terminal dimerization domain</kwd><kwd>IBV, infectious bronchitis virus</kwd><kwd>MHV, mouse hepatitis virus</kwd><kwd>ACE2, Angiotensin I converting enzyme 2</kwd><kwd>HIV, human immunodeficiency virus</kwd><kwd>IVIg, intravenous gammaglobulin</kwd><kwd>PLP, papain-like protease</kwd><kwd>LPV, Lopinavir</kwd><kwd>RTV, ritonavir</kwd><kwd>RDV, Remdesivir</kwd><kwd>NO, Nitric oxide</kwd><kwd>Mpro, Main protease</kwd><kwd>HLA, human leukocyte antigen</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0030">Coronavirus is a type of single-stranded RNA (ssRNA) virus [<xref rid="bib1" ref-type="bibr">1</xref>] Before the emergence of Sars-CoV-2, there are 6 known human coronaviruses, including the Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). The symptoms caused by Sars-CoV-2 infection include acute respiratory distress syndrome (~29%), acute cardiac injury (~12%) or acute kidney injury (~7%) [<xref rid="bib2" ref-type="bibr">2</xref>], implying that Sars-CoV-2 may infect various human tissues. COVID-19 is a highly infectious disease [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>] associated with high mortality [<xref rid="bib5" ref-type="bibr">5</xref>]. SARS-CoV-2, the virus responsible for COVID-19, is a betacoronavirus [<xref rid="bib6" ref-type="bibr">6</xref>]. The previous name for this virus was Sars-CoV-2. The genome of SARS-CoV-2 has been sequenced [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib8" ref-type="bibr">8</xref>]. The genomic sequence of SARS-CoV-2 has 96% similarity to the bat-coronavirus and 76.5% identity to the SARS-CoV [<xref rid="bib9" ref-type="bibr">9</xref>]. Although there are no approved drugs or vaccines for COVID-19, some clinical trials are in progress [<xref rid="bib10" ref-type="bibr">10</xref>]. Lopinavir and Ritonavir were used in preliminary clinical studies [<xref rid="bib3" ref-type="bibr">3</xref>].</p><p id="p0035">Nevertheless, in the past two decades, a massive amount of work has been done to understand the molecular basis of the coronavirus infection and evolution, develop an effective treatment in forms of both vaccines and antiviral drugs, and propose efficient measures for viral detection and prevention [<xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>]. Structures of many individual proteins of SARS, MERS, and related coronaviruses, as well as their biological interactions with other viral and host proteins, have been explored along with the experimental testing of anti-viral properties of small compounds [<xref rid="bib14" ref-type="bibr">[14]</xref>, <xref rid="bib15" ref-type="bibr">[15]</xref>, <xref rid="bib16" ref-type="bibr">[16]</xref>]. In this context, the use of bioinformatics approaches may help fill the gap of missing data and improve the process of knowledge discovery by elucidating molecular mechanisms behind virus replication, the process of viral attachment to the host cells and the effect on the host molecular pathways [<xref rid="bib17" ref-type="bibr">17</xref>]. The final understanding of the molecular action of the virus may improve or accelerate the development of anti-viral therapeutic approaches using information and data available for other coronaviruses.</p><p id="p0040">Therefore, understanding the molecular effects of this virus on human proteins play a pivotal role in prioritizing pharmacological strategies [<xref rid="bib18" ref-type="bibr">18</xref>]. In this review, the crystal structure of the SARS-CoV-2 nucleocapsid N-terminal domain (termed as SARS-CoV-2 N-NTD), as a model for understanding the molecular interactions that govern SARS-CoV-2 N-NTD binding to ribonucleotides is described. and the unique RNA binding site characteristics are discussed, which in turn will aid in the development of new drugs that interfere with viral N protein and viral replication in SARS-CoV-2, and highly related virus SARS-CoV. Furthermore, it is attempted to propose suitable vaccine candidates by identifying B-Cell and T-cell epitopes with computational approaches for drug and vaccine design.</p></sec><sec id="sec2"><label>2</label><title>Structural genomics of 2019 Wuhan novel coronavirus</title><p id="p0045">Structures of many individual proteins of SARS, MERS, and related coronaviruses, as well as their biological interactions with other viral and host proteins, have been explored along with the experimental testing of anti-viral properties of small compounds [<xref rid="bib16" ref-type="bibr">16</xref>]. However, experimental data of the same scale for Sars-CoV-2 may take years to obtain by the research community. By leveraging the previously known information on genome sequences as well as protein structure and function, bioinformaticians have been successfully helping the virologists by structurally characterizing proteins of novel viruses, determining the evolutionary trajectories, identifying interactions with host proteins, and providing other important biological insights. In particular, a plethora of results have been achieved through comparative, or homology, modeling principles [<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib20" ref-type="bibr">20</xref>]. In addition to the global structural genomics initiatives focusing on determining the 3D structures of proteins on a genome-scale [<xref rid="bib21" ref-type="bibr">21</xref>] and specific efforts on rapid structural characterization of proteins in emerging viruses [<xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib23" ref-type="bibr">23</xref>], multiple works have used comparative modeling to predict the structures of protein-protein interaction complexes [<xref rid="bib24" ref-type="bibr">[24]</xref>, <xref rid="bib25" ref-type="bibr">[25]</xref>, <xref rid="bib26" ref-type="bibr">[26]</xref>], facilitating structure-based drug discovery [<xref rid="bib20" ref-type="bibr">20</xref>,<xref rid="bib27" ref-type="bibr">27</xref>,<xref rid="bib28" ref-type="bibr">28</xref>], inferring protein functions [<xref rid="bib29" ref-type="bibr">29</xref>], determining the macromolecular interaction network [<xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>], and providing molecular insights into viral evolution [<xref rid="bib33" ref-type="bibr">[33]</xref>, <xref rid="bib34" ref-type="bibr">[34]</xref>, <xref rid="bib35" ref-type="bibr">[35]</xref>].</p><p id="p0050">By providing a comprehensive structural genomics and interactomics road-maps of Sars-CoV-2 and using this information to infer the possible functional differences and similarities with the related SARS coronavirus, Sars-CoV-2 has 16 predicted non-structural proteins constituting a polyprotein, followed by 13 downstream ORFs: Surface, ORF3a, ORF3b, Envelope, Membrane, ORF6, ORF7a, ORF7b, ORF8, Nucleocapsid, ORF9a, ORF9b, and ORF10. The three viral species whose proteins shared the highest similarity were consistently the same: human SARS (SARS- Cov), bat coronavirus (BtCoV), as well as another bat betacoronavirus (BtRf-BetaCoV) [<xref rid="bib36" ref-type="bibr">36</xref>].</p></sec><sec id="sec3"><label>3</label><title>RNA binding domain of SARS-CoV-2 nucleocapsid protein</title><p id="p0055">SARS-CoV-2 is a betacoronavirus with single-stranded RNA genomes, like MERS-CoV and SARS-CoV. The first two-thirds of viral 30&#x000a0;kb RNA genome, mainly named as ORF1a/b region, translates into two polyproteins (pp1a and pp1ab) and encodes most of the non-structural proteins (nsp) [<xref rid="bib37" ref-type="bibr">37</xref>]. The rest parts of the virus genome encode accessory proteins and four essential structural proteins, including spike (S) glycoprotein, small envelope (E) protein, matrix (M) protein, and nucleocapsid (N) protein [<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref>] Current antiviral drugs developed to treat coronavirus (CoV) infections primarily target S protein, the 3C-like (3CL) and papain-like (PLP) proteases [<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib40" ref-type="bibr">40</xref>]. Because mutant viruses in the S protein is prone to escape the targeted therapeutic with different host-cell receptor binding patterns [<xref rid="bib39" ref-type="bibr">39</xref>], as well as antibody-dependent enhancement (ADE) effects of S protein antibodies are found in MERS coronavirus [<xref rid="bib41" ref-type="bibr">41</xref>], there are several limitations on targeting S protein for antiviral approaches. Antiviral protease inhibitors may nonspecifically act on the cellular homologous protease, resulting in host cell toxicity and severe side effects. Therefore, novel antiviral strategies are needed to combat acute respiratory infections caused by this novel coronavirus SARS-CoV-2 (<xref rid="fig1" ref-type="fig">Fig. 1</xref>
).<fig id="fig1"><label>Fig. 1</label><caption><p>Schematic diagram of the SARS coronavirus structure. Like all coronaviruses, Sars-CoV-2 consist of a minimum of three viral proteins namely spike protein (S), a type of glycoprotein, a membrane protein (M) that spans the membrane and an envelope protein (E), a highly hydrophobic protein that covers the entire structure of the coronavirus. The spike (S) glycoprotein in the coronavirus recognizes the host cell receptors and causes an important role in viral infection.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0060">The CoV N protein is a multifunctional RNA-binding protein necessary for viral RNA transcription and replication [<xref rid="bib42" ref-type="bibr">42</xref>]. It plays many pivotal roles in forming helical ribonucleoproteins during packaging the RNA genome, regulating viral RNA synthesis during replication, transcription and modulating infected cell metabolism [<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib43" ref-type="bibr">43</xref>]. The primary functions of N protein are binding to the viral RNA genome, and packing them into a long helical nucleocapsid structure or ribonucleoprotein (RNP) complex [<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]. <italic>In vitro</italic> and <italic>in vivo</italic> experiments revealed that N protein bound to leader RNA, and was critical for maintaining highly ordered RNA conformation suitable for replicating, and transcribing the viral genome [<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib45" ref-type="bibr">45</xref>,<xref rid="bib46" ref-type="bibr">46</xref>]. More studies implicated that N protein regulated host-pathogen interactions, such as actin reorganization, host cell cycle progression, and apoptosis [<xref rid="bib47" ref-type="bibr">47</xref>,<xref rid="bib48" ref-type="bibr">48</xref>]. The N protein is also a highly immunogenic and abundantly expressed protein during infection, capable of inducing protective immune responses against SARS-CoV and SARS-CoV-2 [<xref rid="bib49" ref-type="bibr">[49]</xref>, <xref rid="bib50" ref-type="bibr">[50]</xref>, <xref rid="bib51" ref-type="bibr">[51]</xref>]. The common domain architectures of coronavirus N protein are consisting of three distinct but highly conserved parts: An N-terminal RNA-binding domain (NTD), a C-terminal dimerization domain (CTD), and intrinsically disordered central Ser/Arg (SR)-rich linker. Previous studies have revealed that the NTD are responsible for RNA binding, CTD for oligomerization, and (SR)-rich linker for primary phosphorylation, respectively [<xref rid="bib52" ref-type="bibr">[52]</xref>, <xref rid="bib53" ref-type="bibr">[53]</xref>, <xref rid="bib54" ref-type="bibr">[54]</xref>]. The crystal structures of SARS-CoV N-NTD [<xref rid="bib55" ref-type="bibr">55</xref>], infectious bronchitis virus (IBV) N-NTD [<xref rid="bib56" ref-type="bibr">56</xref>,<xref rid="bib57" ref-type="bibr">57</xref>], HCoV-OC43 N-NTD [<xref rid="bib53" ref-type="bibr">53</xref>] and mouse hepatitis virus (MHV) N-NTD [<xref rid="bib58" ref-type="bibr">58</xref>] have been solved. The CoVs N-NTD have been found to associate with the 3&#x02032; end of the viral RNA genome, possibly through electrostatic interactions. Additionally, several critical residues have been identified for RNA binding and virus infectivity in the N-terminal domain of coronavirus N proteins [<xref rid="bib58" ref-type="bibr">[58]</xref>, <xref rid="bib59" ref-type="bibr">[59]</xref>, <xref rid="bib60" ref-type="bibr">[60]</xref>]. However, the structural and mechanistic basis for newly emerged novel SARS-CoV-2 N protein remains largely unknown. Understanding these aspects should facilitate the discovery of agents that specifically block the coronavirus replication, transcription and viral assembly [<xref rid="bib61" ref-type="bibr">61</xref>]. Kang et al. [<xref rid="bib62" ref-type="bibr">62</xref>] reported the crystal structure of SARS-CoV-2 nucleocapsid N-terminal domain (termed as SARS-CoV-2 N-NTD), as a model for understanding the molecular interactions that govern SARS-CoV-2 N-NTD binding to ribonucleotides. This finding will aid in the development of new drugs that interfere with viral N protein and viral replication in SARS-CoV-2, and highly related virus SARS-CoV [<xref rid="bib62" ref-type="bibr">62</xref>].</p></sec><sec id="sec4"><label>4</label><title>Single-cell RNA sequencing of human tissues</title><p id="p0065">Angiotensin I converting enzyme 2 (ACE2), is the host receptor by Sars-CoV-2 to infect human cells. Viruses bind to host receptors on the target cell surface to establish infection. Membrane proteins mediated membrane fusion allowed the entry of enveloped viruses [<xref rid="bib63" ref-type="bibr">63</xref>]. As recently reported, both nCoV and SARS-CoV could use ACE2 protein to gain entry into the cells [<xref rid="bib64" ref-type="bibr">64</xref>]. Since the outbreak, many data analysis have shown a wide distribution of ACE2 across human tissues, including lung [<xref rid="bib65" ref-type="bibr">65</xref>], liver [<xref rid="bib66" ref-type="bibr">66</xref>], stomach [<xref rid="bib67" ref-type="bibr">67</xref>], ileum [<xref rid="bib67" ref-type="bibr">67</xref>], colon [<xref rid="bib67" ref-type="bibr">67</xref>] and kidney [<xref rid="bib68" ref-type="bibr">68</xref>], indicating that Sars-CoV-2 may infect multiple organs. However, these data showed that AT2 cells (the main target cell of Sars-CoV-2) in the lung expressed rather low levels of ACE2 [<xref rid="bib68" ref-type="bibr">68</xref>]. Hence, the nCoVs may depend on co-receptor or other auxiliary membrane proteins to facilitate its infection. It is reported that viruses tend to hijack co-expressed proteins as their host factors [<xref rid="bib69" ref-type="bibr">69</xref>]. For example, Hoffmann et al. recently showed that Sars-CoV-2-S use ACE2 for entry and depends on the cellular protease TMPRSS2 for priming [<xref rid="bib70" ref-type="bibr">70</xref>], showing that 2019- nCoV infections also require multiple factors. Understanding the receptors&#x02019; usage by the viruses could facilitate the development of intervention strategies. Therefore, identifying the potential co-receptors or auxiliary membrane proteins for Sars-CoV-2 is of great significance.</p><p id="p0070">Although ACE2 is reported to be expressed in the lung, liver, stomach, ileum, kidney, and colon, its expressing levels are rather low, especially in the lung [<xref rid="bib71" ref-type="bibr">71</xref>]. Sars-CoV-2 may use co-receptors/auxiliary proteins as ACE2 partners to facilitate the virus entry [<xref rid="bib72" ref-type="bibr">72</xref>]. To identify the potential candidates [<xref rid="bib73" ref-type="bibr">73</xref>], explored the single-cell gene expression atlas including 119&#x000a0;cell types of 13 human tissues and analyzed the single-cell co-expression spectrum of 51 reported RNA virus receptors and 400 other membrane proteins. Consistent with other recent reports [<xref rid="bib73" ref-type="bibr">73</xref>], confirmed that ACE2 was mainly expressed in lung AT2, liver cholangiocyte, colon colonocytes, esophagus keratinocytes, ileum ECs, rectum ECs, stomach epithelial cells, and kidney proximal tubules. Intriguingly [<xref rid="bib73" ref-type="bibr">73</xref>], found that the candidate co-receptors, manifesting the most similar expression patterns with ACE2 across 13 human tissues, are all peptidases, including ANPEP, DPP4, and ENPEP. Among them, ANPEP and DPP4 are the known receptors for human CoVs, suggesting ENPEP as another potential receptor for human CoVs.</p></sec><sec id="sec5"><label>5</label><title>Receptors of human coronaviruses</title><p id="p0075">The viruses target host cells via binding host receptors before engaging the infection cycle. ACE2 was proved to be the cell receptor of Sars-CoV-2, the same receptor as SARS-CoV [<xref rid="bib65" ref-type="bibr">65</xref>,<xref rid="bib70" ref-type="bibr">70</xref>]. The expression profiles of ACE2 across different cell types of different organs will reveal clues of the virus transmission routes and its potential pathogenesis. In previous studies, ACE2 was found to express in the esophagus upper and stratified epithelial cells, absorptive enterocytes from ileum and colon, alveolar type II cells in the lung, liver cholangiocyte and kidney proximal tubules [<xref rid="bib66" ref-type="bibr">66</xref>,<xref rid="bib67" ref-type="bibr">67</xref>]. These findings suggested that the clinical symptoms of hepatic failure, respiratory injury, acute kidney injury or diarrhoea may be associated with the pervasive ACE2 expressing cells in these tissues.</p><p id="p0080">However, we and others found that ACE2 is lowly expressed, especially in the lung (the main target organ of nCoVs), raising the possible existence of co-receptors facilitating nCoV infection. It is well recognized that ssRNA viruses tend to have multiple receptors [<xref rid="bib69" ref-type="bibr">69</xref>]. For example, ACE2, CD209 (Dendritic Cell-Specific ICAM-3-Grabbing Non-Integrin 1), CLEC4G (C-type lectin domain family 4 member G) and CLEC4M (C-type lectin domain family 4 member M) are receptors of SARS-CoV [<xref rid="bib71" ref-type="bibr">71</xref>,<xref rid="bib74" ref-type="bibr">74</xref>]. Also, other membrane proteins may also assist virus entry [<xref rid="bib63" ref-type="bibr">63</xref>]. Since the viral receptors and co-receptors should be co-expressed on the same cell types, single-cell co-expression patterns covering 400 membrane proteins and 51 known viral receptors was analyzed [<xref rid="bib64" ref-type="bibr">64</xref>]. After calculating gene expression similarity, they found ANPEP, ENPEP and DPP4 are the top three genes correlated with ACE4 (R&#x000a0;&#x0003e;&#x000a0;0.8). Interestingly, both ANPEP and DPP4 are viral receptors of human coronaviruses [<xref rid="bib75" ref-type="bibr">75</xref>], while ENPEP is also a peptidase, despite that its involvement in virus infection is unclear. For mysterious reasons, human coronaviruses use peptidases as their receptors [<xref rid="bib76" ref-type="bibr">76</xref>]. In addition, Li et al. [<xref rid="bib77" ref-type="bibr">77</xref>] showed co-expression profiles of these molecules, indicating that different human CoVs target similar cell types across different human tissues.</p></sec><sec id="sec6"><label>6</label><title>General treatment for viral infection</title><p id="p0085">Currently, there is no registered treatment or vaccine for the disease. In the absence of a specific treatment for this novel virus, there is an urgent need to find an alternative solution to prevent and control the replication and spread of the virus.</p><sec id="sec6.1"><label>6.1</label><title>Nutritional interventions</title><p id="p0090">Vitamin A supplementation reduced morbidity and mortality in different infectious diseases, such as measles, diarrheal disease, measles-related pneumonia, human immunodeficiency virus (HIV) infection, and malaria, as described by Semba et al. [<xref rid="bib78" ref-type="bibr">78</xref>]. Keil et al. [<xref rid="bib79" ref-type="bibr">79</xref>] had reported that vitamin B2 and UV light effectively reduced the titer of MERS-CoV in human plasma products. Atherton et al. [<xref rid="bib80" ref-type="bibr">80</xref>] had reported that vitamin C increased the resistance of chick embryo tracheal organ cultures to avian coronavirus infection. In addition, the decreased vitamin D status in calves had been reported to cause the infection of Bovine coronavirus [<xref rid="bib81" ref-type="bibr">81</xref>]. Vitamin E deficiency had been reported to intensify the myocardial injury of coxsackievirus B3 (a kind of RNA viruses) infection in mice [<xref rid="bib82" ref-type="bibr">82</xref>]. Protection D1, the omega-3 PUFA-derived lipid mediator, could markedly attenuate influenza virus replication via RNA export machinery [<xref rid="bib83" ref-type="bibr">83</xref>]. Dietary selenium deficiency that causes oxidative stress in the host can alter a viral genome so that a normally benign or mildly pathogenic virus can become highly virulent in the deficient host under oxidative stress [<xref rid="bib84" ref-type="bibr">84</xref>]. The combination of zinc and pyrithione at low concentrations inhibits the replication of SARS coronavirus [<xref rid="bib85" ref-type="bibr">85</xref>]. Iron is required for both host and pathogen and iron deficiency can impair host immunity, while iron overload can cause oxidative stress to propagate harmful viral mutations [<xref rid="bib86" ref-type="bibr">86</xref>].</p></sec><sec id="sec6.2"><label>6.2</label><title>Immunoenhancers</title><p id="p0095">A combination of interferon-&#x003b1;-2a with ribavirin was administered to patients with severe MERS-CoV infection and the survival of these patients was improved [<xref rid="bib87" ref-type="bibr">87</xref>]. During the SARS outbreak in 2003, Intravenous gammaglobulin (IVIg) was used extensively in Singapore. However, one-third of critically ill patients developed venous thromboembolism including pulmonary embolism despite the use of low-molecular-weight heparin prophylactic [<xref rid="bib88" ref-type="bibr">88</xref>]. Thymosin &#x003b1;-1 could increase resistance to glucocorticoid-induced death of the thymocyte [<xref rid="bib89" ref-type="bibr">89</xref>]. Thymosin &#x003b1;-1 could also be used as an immune enhancer to SARS patients and it was effective in controlling the spread of the disease [<xref rid="bib90" ref-type="bibr">90</xref>,<xref rid="bib91" ref-type="bibr">91</xref>]. Thymopentin (TP5, munox), a synthetic pentapeptide corresponding to the active site of thymopoietin, had been shown to restore antibody production in old mice [<xref rid="bib92" ref-type="bibr">92</xref>]. levamisole can act as either an immunostimulant agent or an immunosuppressive agent depending upon the dosing and the timing [<xref rid="bib93" ref-type="bibr">93</xref>]. Luo et al. [<xref rid="bib94" ref-type="bibr">94</xref>] had speculated that nucleocapsid protein (NP) of SARS-CoV played an important role in the process of virus particle assembly and release and it might also bind to human cyclophilin A.</p></sec><sec id="sec6.3"><label>6.3</label><title>Coronavirus-specific treatments</title><p id="p0100">Chymotrypsin-like (3C-like) and papain-like protease (PLP) are coronavirus encoded protein. They have an essential function for coronaviral replication and also have an additional function for inhibition of host innate immune responses [<xref rid="bib95" ref-type="bibr">95</xref>]. Cinanserin, an old drug, is well-known for serotonin receptor antagonists. It could inhibit the 3 chymotrypsin-like (3C-like) protease and was a promising inhibitor of replication of SARS-CoV [<xref rid="bib96" ref-type="bibr">96</xref>]. Flavonoids are an important class of natural products and have several subgroups, which include chalcones, flavones, flavonols, and isoflavones [<xref rid="bib97" ref-type="bibr">97</xref>]. Other flavonoids (Herbacetin, isobavachalcone, quercetin 3-&#x003b2;-d-glucoside, and helichrysetin) were also found to be able to block the enzymatic activity of MERS-CoV/3CLpro [<xref rid="bib98" ref-type="bibr">98</xref>]. Papain-like protease (PLP) of human coronavirus is a novel viral-encoded deubiquitinase and is an IFN antagonist for inhibition of host innate antiviral immune response. Diarylheptanoids is a natural product and is extracted from the stem bark of Alnus japonica. It was able to inhibit papain-like protease of SARS-CoV [<xref rid="bib95" ref-type="bibr">95</xref>].</p><p id="p0105">Angiotensin-converting enzyme-2 (ACE2) is a type I integral membrane protein which that functions as a carboxypeptidase and is the first human homolog of ACE. Besides, ACE2 is also a functional receptor of SARS-CoV and it mediates virus entry into the cell through binding with spike (S) protein [<xref rid="bib99" ref-type="bibr">99</xref>,<xref rid="bib100" ref-type="bibr">100</xref>]. Zhang et al. [<xref rid="bib101" ref-type="bibr">101</xref>] reported that COVID-19 used ACE2 as a sole receptor for the entry, but did not use other coronavirus receptors, aminopeptidase N and dipeptidyl peptidase, for the entry. Blocking the binding of S protein to ACE2 is important for the treatment of SARS-CoV infection [<xref rid="bib102" ref-type="bibr">102</xref>]. One recombinant human monoclonal antibody (mAb) (single-chain variable region fragments, scFvs 80R) against the S1 domain of S protein of SARS-CoV from two nonimmune human antibody libraries. The mAb could efficiently neutralize SARS-CoV and inhibit syncytia formation between cells expressing the S protein and those expressing the SARS-CoV receptor ACE2 were found by Sui et al. [<xref rid="bib103" ref-type="bibr">103</xref>].</p><p id="p0110">Chloroquine has many interesting biochemical properties including antiviral effects. In addition, it had been used against viral infection [<xref rid="bib104" ref-type="bibr">104</xref>]. Emodin is an anthraquinone compound derived from genus Rheum boosted protease inhibitor in the treatment of HIV infection. Lopinavir (LPV) is usually combined with ritonavir (RTV) to increase and Polygonum and it is also a virucidal agent [<xref rid="bib105" ref-type="bibr">105</xref>]. Emodin could significantly block the interaction between the S protein of SARS-CoV and ACE2 [<xref rid="bib106" ref-type="bibr">106</xref>]. Promazine, an anti-psychotic drug, shares a similar structure with emodin. It has been found to exhibit a significant effect in inhibiting the replication of SARS-CoV [<xref rid="bib107" ref-type="bibr">107</xref>]. As compared to emodin, promazine exhibited potent inhibition of the binding of S protein to ACE2. These findings suggested that emodin and promazine might be able to inhibit SARS-CoV infectivity by blocking the interaction of S protein and ACE2. Therefore, the monoclonal antibody (scFv80R), chloroquine, emodin, and promazine could be used as choices for the treatment of COVID-19. Nicotianamine is an important metal-ligand in plants [<xref rid="bib108" ref-type="bibr">108</xref>] and it is found a novel angiotensin-converting enzyme-2 inhibitor in soybean [<xref rid="bib109" ref-type="bibr">109</xref>]. So, it is another potential option to be used to reduce the infection of COVID-19.</p></sec><sec id="sec6.4"><label>6.4</label><title>Antiviral treatments</title><p id="p0115">Ribavirin, a broad-spectrum antiviral agent, is routinely used to treat hepatitis C [<xref rid="bib110" ref-type="bibr">110</xref>]. Morgenstern et al. [<xref rid="bib111" ref-type="bibr">111</xref>] had reported that ribavirin and interferon-&#x003b2; synergistically inhibited the replication of SARS-associated coronavirus in animal and human cell lines. Given adverse reactions and the lack of <italic>in vitro</italic> efficacy, the use of ribavirin should be seriously considered for the treatment of COVID-19, even in combination with other antiviral drugs. The combination of lopinavir (LPV) with ritonavir (RTV) is widely used as a boosted protease inhibitor in the treatment of HIV infection [<xref rid="bib112" ref-type="bibr">112</xref>]. Kim et al. [<xref rid="bib113" ref-type="bibr">113</xref>] had also reported a successful case of MERS-CoV disease treated with triple combination therapy LPV/RTV, ribavirin, and IFN-&#x003b1;2a. Remdesivir (RDV), a nucleoside analog GS-5734, had been reported to inhibit human and zoonotic coronavirus <italic>in vitro</italic> and to restrain severe acute respiratory syndrome coronavirus (SARS-CoV) <italic>in vivo</italic> [<xref rid="bib114" ref-type="bibr">114</xref>]. Recently, the antiviral activity of RDV and IFN-&#x003b2; was found to be superior to that of LPV/RTV&#x02013;IFN&#x02013;&#x003b2; against MERS-CoV <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="bib115" ref-type="bibr">115</xref>]. Therefore, the use of RDV with IFN-&#x003b2; could be a better choice for the treatment of COVID-19 comparing with that of the triple combination of LPV/RTV&#x02013;IFN&#x02013;&#x003b2;. However, randomized and controlled trials are still needed to determine the safety and efficacy of remdesivir. Yamamoto et al. [<xref rid="bib116" ref-type="bibr">116</xref>] had found that nelfinavir could strongly inhibit the replication of SARS-CoV.</p><p id="p0120">Arbidol and its derivatives, arbidol mesylate, had been reported to have antiviral activity against the pathogen of SARS in the cell cultures and arbidol mesylate was nearly 5 times as effective as arbidol in reducing the reproduction of SARS virus in the cultured cells [<xref rid="bib117" ref-type="bibr">117</xref>]. Nitric oxide (NO) is a gas with diverse biological activities and is produced from arginine by NO synthases [<xref rid="bib118" ref-type="bibr">118</xref>]. Akerstr&#x000f6;m et al. [<xref rid="bib119" ref-type="bibr">119</xref>] had reported that organic NO donor, S-nitroso- N-acetylpenicillamine, could significantly inhibit the replication cycle of SARS-CoV in a concentration-dependent manner. Therefore, NO inhalation could be also chosen as an option for the treatment of severely COVID-19 infected patients (<xref rid="tbl1" ref-type="table">Table 1</xref>
).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Treatment options available for COVID&#x02010;19.</p></caption><alt-text id="alttext0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Compounds</th><th>Virus target</th><th>Functions</th><th>Representative References</th></tr></thead><tbody><tr><td colspan="4" align="left">General treatments for viral infection</td></tr><tr><td colspan="4" align="left">Nutritional interventions</td></tr><tr><td align="left">Vitamin A</td><td align="left">Measles virus, avian coronavirus</td><td align="left">Prevention of lung infection.</td><td align="left">(Semba 1999)</td></tr><tr><td align="left">B vitamins</td><td align="left">MERS&#x02010;CoV; ventilator&#x02010;induced lung injury</td><td align="left">Enhance their immune system</td><td align="left">(Keil, Bowen et al., 2016)</td></tr><tr><td align="left">Vitamin C</td><td align="left">Avian coronavirus; lower respiratory tract infections</td><td align="left">Act as an antioxidant</td><td align="left">(Atherton, Kratzing et al., 1978)</td></tr><tr><td align="left">Vitamin D</td><td align="left">Bovine coronavirus</td><td align="left">Maintaining bone integrity</td><td align="left">(Nonnecke, McGill et al., 2014)</td></tr><tr><td align="left">Vitamin E</td><td align="left">Coxsackievirus, bovine coronavirus</td><td align="left">Reducing oxidative stress</td><td align="left">(Beck, Kolbeck et al., 1994)</td></tr><tr><td align="left">PUFA<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="left">Influenza virus, human immunodeficiency virus</td><td align="left">Anti&#x02010;inflammatory and pro&#x02010;inflammatory effects.</td><td align="left">(Morita, Kuba et al., 2013)</td></tr><tr><td align="left">Selenium</td><td align="left">Influenza virus, avian coronavirus; viral mutations</td><td align="left">Defense against infectious diseases</td><td align="left">(Rayman 2012)</td></tr><tr><td align="left">Zinc</td><td align="left">Measles virus, SARS&#x02010;CoV</td><td align="left">Maintaining immune system</td><td align="left">(Te Velthuis, van den Worm et al., 2010)</td></tr><tr><td align="left">Iron</td><td align="left">Viral mutations</td><td align="left">Development of recurrent acute respiratory infections</td><td align="left">(Wessling-Resnick 2018)</td></tr><tr><td colspan="4" align="left">Immunoenhancers</td></tr><tr><td align="left">Interferons</td><td align="left">SARS&#x02010;CoV, MERS&#x02010;CoV</td><td align="left">Immune response to virus infection.</td><td align="left">(Momattin, Al-Ali et al., 2018)</td></tr><tr><td align="left">Intravenous gammaglobulin</td><td align="left">SARS&#x02010;CoV</td><td align="left">Increase of viscosity in hypercoagulable states</td><td align="left">(Lew, Kwek et al., 2003)</td></tr><tr><td align="left">Thymosin &#x003b1;&#x02010;1</td><td align="left">SARS&#x02010;CoV</td><td align="left">Increase resistance to glucocorticoid&#x02010;induced death</td><td align="left">(Baumann, Badamchian et al., 1997)</td></tr><tr><td align="left">Thymopentin</td><td align="left">hepatitis B</td><td align="left">Restore antibody production</td><td align="left">(Duchateau, Servais et al., 1985)</td></tr><tr><td align="left">Levamisole</td><td align="left">SARS&#x02010;CoV</td><td align="left">Immunostimulant agent or immunosuppressive agent</td><td align="left">(Joffe, Sukha et al., 1983)</td></tr><tr><td align="left">Cyclosporine A</td><td align="left">SARS&#x02010;CoV, avian infectious bronchitis virus</td><td align="left">Treatment of autoimmune disorders</td><td align="left">(Luo, Luo et al., 2004)</td></tr><tr><td colspan="4" align="left"><bold>Coronavirus&#x02010;specific treatments</bold></td></tr><tr><td colspan="4" align="left">Coronavirus protease inhibitors</td></tr><tr><td colspan="4" align="left">Chymotrypsin&#x02010;like (3C&#x02010;like) inhibitors</td></tr><tr><td align="left">Cinanserin</td><td align="left">SARS&#x02010;CoV</td><td align="left">Serotonin receptor antagonist</td><td align="left">(Chen, Gui et al., 2005)</td></tr><tr><td align="left">Flavonoids</td><td align="left">SARS&#x02010;CoV/MERS&#x02010;CoV</td><td align="left">Antioxidant effects/antiviral abilities</td><td align="left">(Diwan, Ninawe et al., 2017)</td></tr><tr><td colspan="4" align="left">Papain&#x02010;like protease (PLP) inhibitors</td></tr><tr><td align="left">Diarylheptanoids</td><td align="left">SARS&#x02010;CoV</td><td align="left">Anti-inflammatory, antioxidant, antitumor</td><td align="left">(Park, Jeong et al., 2012)</td></tr><tr><td colspan="4" align="left">Spike (S) protein&#x02010;angiotensin&#x02010;converting enzyme&#x02010;2 (ACE2) blockers</td></tr><tr><td align="left">Human monoclonal antibody</td><td align="left">SARS&#x02010;CoV</td><td align="left">Treatment of many&#x000a0;solid tumors</td><td align="left">(Sui, Li et al., 2004)</td></tr><tr><td align="left">Chloroquine</td><td align="left">SARS&#x02010;CoV</td><td align="left">Prevention of malaria in adults</td><td align="left">(Savarino, Boelaert et al., 2003)</td></tr><tr><td align="left">Emodin</td><td align="left">SARS&#x02010;CoV</td><td align="left">Pancreatic disease, inflammatory, and diabetes</td><td align="left">(Vickers 2017)</td></tr><tr><td align="left">Promazine</td><td align="left">SARS&#x02010;CoV</td><td align="left">Using in paranoid and manic-depressive conditions,</td><td align="left">(Cauwenberghs, Feijge et al., 2006)</td></tr><tr><td align="left">Nicotianamine</td><td align="left">SARS&#x02010;CoV</td><td align="left">To reduce the infection</td><td align="left">(Cauwenberghs, Feijge et al., 2006)</td></tr><tr><td colspan="4" align="left"><bold>Antiviral treatments</bold></td></tr><tr><td align="left">Ribavirin</td><td align="left">SARS&#x02010;CoV</td><td align="left">Treatment of hepatitis C</td><td align="left">(Ksiazek, Erdman et al., 2003)</td></tr><tr><td align="left">(LPV)<xref rid="tbl1fnb" ref-type="table-fn">b</xref>/(RTV)<xref rid="tbl1fnC" ref-type="table-fn">c</xref> (Kaletra)</td><td align="left">MERS&#x02010;CoV</td><td align="left">Treatment of HIV infection</td><td align="left">(Tsang and Zhong 2003)</td></tr><tr><td align="left">Remdesivir</td><td align="left">SARS&#x02010;CoV/MERS&#x02010;CoV</td><td align="left">Treatment of Ebola virus disease and Marburg virus</td><td align="left">(Yamamoto, Yang et al., 2004)</td></tr><tr><td align="left">Nelfinavir</td><td align="left">SARS&#x02010;CoV</td><td align="left">Treatment of HIV</td><td align="left">(Mohanasundaram and Sekhar 2018)</td></tr><tr><td align="left">Arbidol</td><td align="left">SARS&#x02010;CoV</td><td align="left">Treatment for influenza infection</td><td align="left">(Khamitov, Loginova et al., 2008)</td></tr><tr><td align="left">Nitric oxide</td><td align="left">SARS&#x02010;CoV</td><td align="left">Treatment of inflammatory airway disease</td><td align="left">(Robbins and Grisham 1997)</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Omega&#x02010;3 polyunsaturated fatty acid.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0015">Lopinavir.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnC"><label>C</label><p id="ntpara0020">Ritonavir.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec7"><label>7</label><title>Prediction of potential drugs for COVID-19</title><sec id="sec7.1"><label>7.1</label><title>Virtual high throughput screening</title><p id="p0125">Computational methods can be utilized for the design and engineering of drugs [<xref rid="bib120" ref-type="bibr">120</xref>,<xref rid="bib121" ref-type="bibr">121</xref>]. The low time requirements of computational methods are conducive for high throughput screening of available drugs to identify potential drugs for novel diseases as well as to predict the adverse effects of novel drugs [<xref rid="bib122" ref-type="bibr">122</xref>]. Development of novel drugs is a time-consuming process and generally, several years of work are required for clinical approval [<xref rid="bib121" ref-type="bibr">121</xref>]. Drug repositioning, also known as repurposing, is an effective strategy to combat novel diseases caused by infectious agents that spread rapidly [<xref rid="bib123" ref-type="bibr">123</xref>]. Drugs that have been approved for some disease, are safe for human use, and only their effectiveness against the disease of interest needs to be established [<xref rid="bib124" ref-type="bibr">124</xref>]. In life-threatening cases, where there is no alternative medicine or vaccine, such a drug repurposing strategy is particularly attractive. However, clinical trials are necessary to ensure that such treatment is better than a placebo [<xref rid="bib125" ref-type="bibr">125</xref>].</p><p id="p0130">Lopinavir and Ritonavir were identified in earlier studies to target the Main protease (Mpro) of SARS virus. The protein sequences of COVID-19 Main protease (Sars-CoV-2 Mpro) and SARS-CoV Mpro are 96% identical [<xref rid="bib126" ref-type="bibr">126</xref>]. In several early studies, the similarities in the sequence of a potential target for COVID-19 to that of the SARS Mpro were utilized to build a model for the structure of SARS- CoV-2 Mpro [<xref rid="bib126" ref-type="bibr">126</xref>]. Homology based models were utilized to screen a library of compounds to predict that Nelfinavir, an approved antiviral protease inhibitor, is a potential drug for COVID-19 [<xref rid="bib122" ref-type="bibr">122</xref>]. The sequence similarity of the SARS-CoV-2 Mpro to the SARS Mpro is sufficiently high to build a good model for the structure of SARS-CoV-2 Mpro [<xref rid="bib123" ref-type="bibr">123</xref>,<xref rid="bib127" ref-type="bibr">127</xref>]. However, the predictions of virtual screening studies and binding energy calculations are generally more accurate if a high-resolution experimental structure of the target is available.</p><p id="p0135">The recent availability of the genomic sequence of the virus responsible for COVID-19, as well as the experimentally determined three-dimensional structure of the Mpro was utilized as the target for virtual high throughput screening [<xref rid="bib120" ref-type="bibr">120</xref>], indicating that the results confirm earlier preliminary reports based on studies of homologs that some of the drugs approved for the treatment of other viral infections also have the potential for the treatment of COVID-19. Therefore, approved anti-viral drugs that target proteases were ranked for potential effectiveness against COVID-19 and novel candidates for drug repurposing were identified.</p></sec><sec id="sec7.2"><label>7.2</label><title>Drug and vaccine design against novel coronavirus spike protein</title><p id="p0140">There is an urgent need for the development of anti-viral drugs and vaccines against the 2019- nCov virus due to the high mortality rate of patients. During the epidemic and pandemic outbreak of new viral pathogens, the conventional method of development of drugs and vaccination is not possible to control as it is a time-consuming process [<xref rid="bib128" ref-type="bibr">128</xref>,<xref rid="bib129" ref-type="bibr">129</xref>]. Consequently, the rapid approach based on in-silico informatics has become very popular with recent advances in the sequencing of many pathogen genomes and protein sequence databases [<xref rid="bib130" ref-type="bibr">[130]</xref>, <xref rid="bib131" ref-type="bibr">[131]</xref>, <xref rid="bib132" ref-type="bibr">[132]</xref>]. The continuous increase of patients and a high mortality rate of Sars-CoV-2 infection highlight the urgent need for the development of a safe and effective vaccine [<xref rid="bib133" ref-type="bibr">133</xref>]. The aim of this is to use to computational approach to design both anti-viral drug and vaccine candidates. The spike protein in the novel coronavirus sequence is used to design both anti-viral drug and vaccine candidates. For anti-viral drug design, receptor-binding protein of novel coronavirus present in the N-terminal of spike protein is homology modelled and used as a protein receptor [<xref rid="bib134" ref-type="bibr">134</xref>]. 3C like proteinase (3CLpro) plays a role in viral pathogenicity and replication by clevaging the polyprotein. The inhibitors of 3CLpro can block the clevage reaction thereby controlling viral replication and pathogenicity [<xref rid="bib135" ref-type="bibr">135</xref>]. The natural inhibitors were used as ligands and docked with homology modelled coronavirus receptor binding protein [<xref rid="bib136" ref-type="bibr">136</xref>]. For vaccine design, the full sequence of the spike protein of novel coronavirus is used to predict B-cell and T-cell epitopes. The select best T-cell epitopes based on antigenicity used as peptides and docked with human allele protein.</p><p id="p0145">The computational approach is proposed for drug and vaccine design [<xref rid="bib120" ref-type="bibr">120</xref>]. To explore suitable natural inhibitors for the N-terminal receptor-binding domain of spike protein, the spike protein sequences were collected from a protein database. And also they were analyzed with various bioinformatics tools, attempting to identify suitable vaccine candidates by identifying B-Cell and T-cell epitopes [<xref rid="bib137" ref-type="bibr">137</xref>]. In the drug design, the tanshinone Iia and methyl Tanshinonate were identified as natural inhibitors based on the docking score [<xref rid="bib138" ref-type="bibr">138</xref>]. In the vaccine design, B-cell epitope VLLPLVSSQCVNLTTRTQLPPAYTN was found to have the highest antigenicity. FVFLVLLPL of MHC class-I allele and FVFLVLLPL of MHC class-II allele were identified as best peptides based on several alleles and antigenicity scores [<xref rid="bib139" ref-type="bibr">139</xref>]. Therefore, identifies natural inhibitors and putative antigenic epitopes might be useful as effective drug and vaccine candidates for the eradication of novel coronavirus.</p></sec><sec id="sec7.3"><label>7.3</label><title>Epitope-based peptide vaccine design and target site characterization against novel coronavirus</title><p id="p0150">Structural proteins are important targets for vaccine and anti-viral drug development due to their indispensable function to fuse and enter into the host cell [<xref rid="bib140" ref-type="bibr">140</xref>]. SARS-CoV-2 utilizes glycosylated spike (S) protein to gain entry into host cells. The S protein is a trimeric class I fusion protein and exists in a metastable prefusion conformation that undergoes a dramatic structural rearrangement to fuse the viral membrane with the host-cell membrane [<xref rid="bib141" ref-type="bibr">141</xref>,<xref rid="bib142" ref-type="bibr">142</xref>]. The S protein includes the receptor binding S1-subunit and the membrane fusion S2-subunit. The S1 subunit receptor-binding domain (RDB) is specifically recognized by the host receptor. When the S1 subunit binds to a host-cell receptor, the prefusion trimer is destabilized, resulting in the shedding of the S1 subunit, and the state transition of the S2 subunit to a stable postfusion conformation [<xref rid="bib143" ref-type="bibr">143</xref>]. The critical function of the S protein can be a breakthrough in vaccine design and development.</p><p id="p0155">Great efforts are being made for the discovery of antiviral drugs, but there are no licensed therapeutic or vaccine for the treatment of SARS-CoV-2 infection available in the market. Developing an effective treatment for SARS-CoV-2 is, therefore, a research priority. It is time-consuming and expensive to design novel vaccines against viruses by the use of kits and related antibodies [<xref rid="bib144" ref-type="bibr">144</xref>]. Thus, choosing the method of immune-informatics is more efficient and more applicable for deep analysis of viral antigens, B- and T-cell linear epitope prediction, and evaluation of immunogenicity and virulence of pathogens. Among those can be analyzed, B-cell can recognize and activate defense responses against viral infection, T-cell and antibody reactions may recover extreme respiratory infection (<xref rid="fig2" ref-type="fig">Fig. 2</xref>
).<fig id="fig2"><label>Fig. 2</label><caption><p>The overall workflow of computational drug and vaccine design by using a novel coronavirus spike protein.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p><p id="p0160">The immune-informatics approaches to identify B- and T-cell epitopes for surface glycoprotein (S) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles was taken by Li et al. [<xref rid="bib145" ref-type="bibr">145</xref>]. Four B cell epitopes, two MHC class-I and nine MHC class-II binding T-cell epitopes, which showed highly antigenic features were identified. Allergenicity, toxicity and physiochemical properties analysis confirmed the specificity and selectivity of epitopes. The stability and safety of epitopes were confirmed by digestion analysis. No mutations were observed in all the selected B- and T-cell epitopes across all isolates from different locations worldwide. Epitopes were thus identified and some of them can be potential candidates for vaccine development, as described by Li et al. [<xref rid="bib145" ref-type="bibr">145</xref>].</p></sec></sec><sec id="sec8"><label>8</label><title>Conclusion</title><p id="p0165">As noted before, COVID-19 has become a global concern, due to widespread outbreaks and lack of treatment. Therefore, it is necessary to find and evaluate treatment methods more quickly in this case computer methods are very effective and helpful. The predicted binding and ranking of drugs will also be useful to interpret the results of ongoing clinical trials that are testing existing drugs for effectiveness against COVID-19. Notwithstanding the limitations, it has been described several diseases and traits which may be causally related to ACE2 expression the lung, which in turn may mediate susceptibility to Sars-CoV-2 infection. In addition, the proteome-wide MR analysis revealed proteins that could lead to changes in ACE2 expression. Subsequent drug repositioning analysis highlighted several candidates that may warrant further investigations. We stress that most of the findings require replications and validation in further studies, especially the part on drug repositioning. Nevertheless, it is believed that this work is of value given the urgency to address the outbreak of Sars-CoV-2.</p></sec><sec id="sec9"><title>Funding</title><p id="p0170">This study was supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004366</institution-id><institution>Tabriz University of Medical Sciences</institution></institution-wrap></funding-source> with grant number 65174.</p></sec><sec id="sec10"><title>Declaration of competing interestCOI</title><p id="p0175">None to declare.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Ahlquist</surname><given-names>P.</given-names></name><name><surname>Noueiry</surname><given-names>A.O.</given-names></name><name><surname>Lee</surname><given-names>W.-M.</given-names></name><name><surname>Kushner</surname><given-names>D.B.</given-names></name><name><surname>Dye</surname><given-names>B.T.</given-names></name></person-group><article-title>Host factors in positive-strand RNA virus genome replication</article-title><source>J. Virol.</source><volume>77</volume><year>2003</year><fpage>8181</fpage><lpage>8186</lpage><pub-id pub-id-type="pmid">12857886</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name><name><surname>Ran</surname><given-names>J.</given-names></name><name><surname>Musa</surname><given-names>S.S.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak</article-title><source>Int. J. Infect. Dis.</source><volume>92</volume><year>2020</year><fpage>214</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">32007643</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Ozma</surname><given-names>M.A.</given-names></name><name><surname>Maroufi</surname><given-names>P.</given-names></name><name><surname>Khodadadi</surname><given-names>E.</given-names></name><name><surname>K&#x000f6;se</surname><given-names>&#x0015e;.</given-names></name><name><surname>Esposito</surname><given-names>I.</given-names></name><name><surname>Ganbarov</surname><given-names>K.</given-names></name></person-group><article-title>Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (Covid-19) during the outbreak period</article-title><source>Inf. Med.</source><volume>28</volume><year>2020</year></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>I Azhar</surname><given-names>E.</given-names></name><name><surname>Madani</surname><given-names>T.A.</given-names></name><name><surname>Ntoumi</surname><given-names>F.</given-names></name><name><surname>Kock</surname><given-names>R.</given-names></name><name><surname>Dar</surname><given-names>O.</given-names></name></person-group><article-title>The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health&#x02014;the latest 2019 novel coronavirus outbreak in Wuhan, China</article-title><source>Int. J. Infect. Dis.</source><volume>91</volume><year>2020</year><fpage>264</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">31953166</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y.-R.</given-names></name><name><surname>Cao</surname><given-names>Q.-D.</given-names></name><name><surname>Hong</surname><given-names>Z.-S.</given-names></name><name><surname>Tan</surname><given-names>Y.-Y.</given-names></name><name><surname>Chen</surname><given-names>S.-D.</given-names></name><name><surname>Jin</surname><given-names>H.-J.</given-names></name></person-group><article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak&#x02013;an update on the status</article-title><source>Mil. Med. Res.</source><volume>7</volume><year>2020</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">31928528</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.-W.</given-names></name><name><surname>Kok</surname><given-names>K.-H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>K.K.-W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg. Microb. Infect.</source><volume>9</volume><year>2020</year><fpage>221</fpage><lpage>236</lpage></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.-M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.-G.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Pathogenicity and transmissibility of 2019-nCoV&#x02014;a quick overview and comparison with other emerging viruses</article-title><source>Microb. Infect.</source><volume>22</volume><issue>2</issue><year>2020</year><fpage>69</fpage><lpage>71</lpage></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name></person-group><article-title>Drug treatment options for the 2019-new coronavirus (2019-nCoV)</article-title><source>Biosci. Trends</source><volume>14</volume><year>2020</year><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">31996494</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name></person-group><article-title>Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains</article-title><source>Nat. Commun.</source><volume>8</volume><year>2017</year><fpage>15092</fpage><pub-id pub-id-type="pmid">28393837</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Cotten</surname><given-names>M.</given-names></name><name><surname>Watson</surname><given-names>S.J.</given-names></name><name><surname>Kellam</surname><given-names>P.</given-names></name><name><surname>Al-Rabeeah</surname><given-names>A.A.</given-names></name><name><surname>Makhdoom</surname><given-names>H.Q.</given-names></name><name><surname>Assiri</surname><given-names>A.</given-names></name></person-group><article-title>Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study</article-title><source>Lancet</source><volume>382</volume><year>2013</year><fpage>1993</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">24055451</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Fathizadeh</surname><given-names>H.</given-names></name><name><surname>Maroufi</surname><given-names>P.</given-names></name><name><surname>Momen-Heravi</surname><given-names>M.</given-names></name><name><surname>Dao</surname><given-names>S.</given-names></name><name><surname>K&#x000f6;se</surname><given-names>&#x0015e;.</given-names></name><name><surname>Ganbarov</surname><given-names>K.</given-names></name></person-group><article-title>Protection and disinfection policies against SARS-CoV-2 (COVID-19)</article-title><source>Inf. Med.</source><volume>28</volume><year>2020</year></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Killerby</surname><given-names>M.E.</given-names></name><name><surname>Biggs</surname><given-names>H.M.</given-names></name><name><surname>Midgley</surname><given-names>C.M.</given-names></name><name><surname>Gerber</surname><given-names>S.I.</given-names></name><name><surname>Watson</surname><given-names>J.T.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus transmission</article-title><source>Emerg. Infect. Dis.</source><volume>26</volume><year>2020</year><fpage>191</fpage><pub-id pub-id-type="pmid">31961300</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>C.-C.</given-names></name><name><surname>Lin</surname><given-names>M.-H.</given-names></name><name><surname>Chuang</surname><given-names>C.-Y.</given-names></name><name><surname>Hsu</surname><given-names>C.-H.</given-names></name></person-group><article-title>Macro domain from Middle East respiratory syndrome coronavirus (MERS-CoV) is an efficient ADP-ribose binding module crystal structure and biochemical studies</article-title><source>J. Biol. Chem.</source><volume>291</volume><year>2016</year><fpage>4894</fpage><lpage>4902</lpage><pub-id pub-id-type="pmid">26740631</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Rosen</surname><given-names>O.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Turner</surname><given-names>H.L.</given-names></name><name><surname>Stevens</surname><given-names>L.J.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name></person-group><article-title>Structural definition of a neutralization-sensitive epitope on the MERS-CoV S1-NTD</article-title><source>Cell Rep.</source><volume>28</volume><year>2019</year><fpage>3395</fpage><lpage>3405. e6</lpage><pub-id pub-id-type="pmid">31553909</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Irwin</surname><given-names>D.M.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name></person-group><article-title>Emergence of SARS-like Coronavirus poses new challenge in China</article-title><source>J. Infect.</source><volume>80</volume><year>2020</year><fpage>350</fpage><lpage>371</lpage></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Guzzi</surname><given-names>P.H.</given-names></name><name><surname>Mercatelli</surname><given-names>D.</given-names></name><name><surname>Ceraolo</surname><given-names>C.</given-names></name><name><surname>Giorgi</surname><given-names>F.M.</given-names></name></person-group><article-title>Master regulator analysis of the SARS-CoV-2/human interactome</article-title><source>bioRxiv</source><volume>9</volume><issue>4</issue><year>2020</year><fpage>982</fpage></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Mart&#x000ed;-Renom</surname><given-names>M.A.</given-names></name><name><surname>Stuart</surname><given-names>A.C.</given-names></name><name><surname>Fiser</surname><given-names>A.</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>R.</given-names></name><name><surname>Melo</surname><given-names>F.</given-names></name><name><surname>&#x00160;ali</surname><given-names>A.</given-names></name></person-group><article-title>Comparative protein structure modeling of genes and genomes</article-title><source>Annu. Rev. Biophys. Biomol. Struct.</source><volume>29</volume><year>2000</year><fpage>291</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">10940251</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Cavasotto</surname><given-names>C.N.</given-names></name><name><surname>Phatak</surname><given-names>S.S.</given-names></name></person-group><article-title>Homology modeling in drug discovery: current trends and applications</article-title><source>Drug Discov. Today</source><volume>14</volume><year>2009</year><fpage>676</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">19422931</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Burley</surname><given-names>S.K.</given-names></name><name><surname>Almo</surname><given-names>S.C.</given-names></name><name><surname>Bonanno</surname><given-names>J.B.</given-names></name><name><surname>Capel</surname><given-names>M.</given-names></name><name><surname>Chance</surname><given-names>M.R.</given-names></name><name><surname>Gaasterland</surname><given-names>T.</given-names></name></person-group><article-title>Structural genomics: beyond the human genome project</article-title><source>Nat. Genet.</source><volume>23</volume><year>1999</year><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">10508510</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Wichapong</surname><given-names>K.</given-names></name><name><surname>Pianwanit</surname><given-names>S.</given-names></name><name><surname>Sippl</surname><given-names>W.</given-names></name><name><surname>Kokpol</surname><given-names>S.</given-names></name></person-group><article-title>Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction</article-title><source>J. Mol. Recogn.: Interdiscipl. J.</source><volume>23</volume><year>2010</year><fpage>283</fpage><lpage>300</lpage></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Ekins</surname><given-names>S.</given-names></name><name><surname>Liebler</surname><given-names>J.</given-names></name><name><surname>Neves</surname><given-names>B.J.</given-names></name><name><surname>Lewis</surname><given-names>W.G.</given-names></name><name><surname>Coffee</surname><given-names>M.</given-names></name><name><surname>Bienstock</surname><given-names>R.</given-names></name></person-group><article-title>Illustrating and homology modeling the proteins of the Zika virus</article-title><source>F1000Research</source><volume>5</volume><year>2016</year></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>F.P.</given-names></name><name><surname>Barkan</surname><given-names>D.T.</given-names></name><name><surname>Eswar</surname><given-names>N.</given-names></name><name><surname>McKerrow</surname><given-names>J.H.</given-names></name><name><surname>Sali</surname><given-names>A.</given-names></name></person-group><article-title>Host&#x02013;pathogen protein interactions predicted by comparative modeling</article-title><source>Protein Sci.</source><volume>16</volume><year>2007</year><fpage>2585</fpage><lpage>2596</lpage><pub-id pub-id-type="pmid">17965183</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>R.B.</given-names></name><name><surname>Alber</surname><given-names>F.</given-names></name><name><surname>Aloy</surname><given-names>P.</given-names></name><name><surname>Davis</surname><given-names>F.P.</given-names></name><name><surname>Korkin</surname><given-names>D.</given-names></name><name><surname>Pichaud</surname><given-names>M.</given-names></name></person-group><article-title>A structural perspective on protein&#x02013;protein interactions</article-title><source>Curr. Opin. Struct. Biol.</source><volume>14</volume><year>2004</year><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">15193311</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.C.</given-names></name><name><surname>Petrey</surname><given-names>D.</given-names></name><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Qiang</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Thu</surname><given-names>C.A.</given-names></name></person-group><article-title>Structure-based prediction of protein&#x02013;protein interactions on a genome-wide scale</article-title><source>Nature</source><volume>490</volume><year>2012</year><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">23023127</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.-Q.</given-names></name><name><surname>Du</surname><given-names>Q.-S.</given-names></name><name><surname>Chou</surname><given-names>K.-C.</given-names></name></person-group><article-title>Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>354</volume><year>2007</year><fpage>634</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">17266937</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Cavasotto</surname><given-names>C.N.</given-names></name><name><surname>Orry</surname><given-names>A.J.</given-names></name><name><surname>Murgolo</surname><given-names>N.J.</given-names></name><name><surname>Czarniecki</surname><given-names>M.F.</given-names></name><name><surname>Kocsi</surname><given-names>S.A.</given-names></name><name><surname>Hawes</surname><given-names>B.E.</given-names></name></person-group><article-title>Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening</article-title><source>J. Med. Chem.</source><volume>51</volume><year>2008</year><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">18198821</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Loewenstein</surname><given-names>Y.</given-names></name><name><surname>Raimondo</surname><given-names>D.</given-names></name><name><surname>Redfern</surname><given-names>O.C.</given-names></name><name><surname>Watson</surname><given-names>J.</given-names></name><name><surname>Frishman</surname><given-names>D.</given-names></name><name><surname>Linial</surname><given-names>M.</given-names></name></person-group><article-title>Protein function annotation by homology-based inference</article-title><source>Genome Biol.</source><volume>10</volume><year>2009</year><fpage>207</fpage><pub-id pub-id-type="pmid">19226439</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Vidalain</surname><given-names>P.-O.</given-names></name><name><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>Virus-host protein interactions in RNA viruses</article-title><source>Microb. Infect.</source><volume>12</volume><year>2010</year><fpage>1134</fpage><lpage>1143</lpage></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Prediction of GCRV virus-host protein interactome based on structural motif-domain interactions</article-title><source>BMC Bioinf.</source><volume>18</volume><year>2017</year><fpage>145</fpage></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Durmu&#x0015f;</surname><given-names>S.</given-names></name><name><surname>&#x000dc;lgen</surname><given-names>K.&#x000d6;.</given-names></name></person-group><article-title>Comparative interactomics for virus&#x02013;human protein&#x02013;protein interactions: DNA viruses versus RNA viruses</article-title><source>FEBS Open Biol.</source><volume>7</volume><year>2017</year><fpage>96</fpage><lpage>107</lpage></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>S.</given-names></name><name><surname>Wan</surname><given-names>X.-F.</given-names></name><name><surname>Conant</surname><given-names>G.</given-names></name><name><surname>Korkin</surname><given-names>D.</given-names></name></person-group><article-title>Extreme evolutionary conservation of functionally important regions in H1N1 influenza proteome</article-title><source>PloS One</source><volume>8</volume><year>2013</year></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Valderramos</surname><given-names>S.G.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Ouyang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Brasil</surname><given-names>P.</given-names></name></person-group><article-title>From mosquitos to humans: genetic evolution of Zika virus</article-title><source>Cell Host Microbe</source><volume>19</volume><year>2016</year><fpage>561</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">27091703</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>H.</given-names></name><name><surname>Kukol</surname><given-names>A.</given-names></name></person-group><article-title>Prediction of ligands to universally conserved binding sites of the influenza a virus nuclear export protein</article-title><source>Virology</source><volume>537</volume><year>2019</year><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">31542626</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Srinivasan</surname><given-names>S.</given-names></name><name><surname>Cui</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Mkandawire</surname><given-names>W.</given-names></name><name><surname>Narykov</surname><given-names>O.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Korkin</surname><given-names>D.</given-names></name></person-group><article-title>Structural Genomics of SARS-CoV-2 Indicates Evolutionary Conserved Functional Regions of Viral Proteins</article-title><source>Viruses</source><volume>12</volume><year>2020</year><fpage>360</fpage></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>17</volume><year>2019</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="book" id="sref38"><person-group person-group-type="author"><name><surname>Sawicki</surname><given-names>S.G.</given-names></name></person-group><chapter-title>Coronavirus genome replication</chapter-title><source>Viral Genome Replication</source><year>2009</year><publisher-name>Springer</publisher-name><fpage>25</fpage><lpage>39</lpage></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.-L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">32075877</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="book" id="sref40"><person-group person-group-type="author"><name><surname>Ramajayam</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>K.-P.</given-names></name><name><surname>Liang</surname><given-names>P.-H.</given-names></name></person-group><chapter-title>Recent Development of 3C and 3CL Protease Inhibitors for Anti-coronavirus and Anti-picornavirus Drug Discovery</chapter-title><year>2011</year><publisher-name>Portland Press Ltd.</publisher-name></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Yount</surname><given-names>B.</given-names></name><name><surname>Gully</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry</article-title><source>PLoS Pathog.</source><volume>16</volume><year>2020</year><object-id pub-id-type="publisher-id">e1008392</object-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>G.W.</given-names></name><name><surname>Stohlman</surname><given-names>S.A.</given-names></name><name><surname>Tahara</surname><given-names>S.M.</given-names></name></person-group><article-title>High affinity interaction between nucleocapsid protein and leader/intergenic sequence of mouse hepatitis virus RNA</article-title><source>J. Gen. Virol.</source><volume>81</volume><year>2000</year><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">10640556</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>Y.</given-names></name><name><surname>Ulasli</surname><given-names>M.</given-names></name><name><surname>Schepers</surname><given-names>H.</given-names></name><name><surname>Mauthe</surname><given-names>M.</given-names></name><name><surname>V&#x02019;kovski</surname><given-names>P.</given-names></name><name><surname>Kriegenburg</surname><given-names>F.</given-names></name></person-group><article-title>Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle</article-title><source>J. Virol.</source><volume>94</volume><year>2020</year></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="book" id="sref44"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>P.S.</given-names></name><name><surname>Sturman</surname><given-names>L.S.</given-names></name></person-group><chapter-title>Background paper functions of the coronavirus nucleocapsid protein</chapter-title><source>Coronaviruses and Their Diseases: Springer</source><year>1990</year><fpage>235</fpage><lpage>238</lpage></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>R.</given-names></name><name><surname>Van Zyl</surname><given-names>M.</given-names></name><name><surname>Fielding</surname><given-names>B.C.</given-names></name></person-group><article-title>The coronavirus nucleocapsid is a multifunctional protein</article-title><source>Viruses</source><volume>6</volume><year>2014</year><fpage>2991</fpage><lpage>3018</lpage><pub-id pub-id-type="pmid">25105276</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>T.K.</given-names></name><name><surname>Wu</surname><given-names>M.P.J.</given-names></name><name><surname>Chen</surname><given-names>S.T.</given-names></name><name><surname>Hou</surname><given-names>M.H.</given-names></name><name><surname>Hong</surname><given-names>M.H.</given-names></name><name><surname>Pan</surname><given-names>F.M.</given-names></name></person-group><article-title>Biochemical and immunological studies of nucleocapsid proteins of severe acute respiratory syndrome and 229E human coronaviruses</article-title><source>Proteomics</source><volume>5</volume><year>2005</year><fpage>925</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">15759315</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>1644</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">18289745</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>P.-K.</given-names></name><name><surname>Chang</surname><given-names>S.C.</given-names></name><name><surname>Huang</surname><given-names>C.-C.</given-names></name><name><surname>Lee</surname><given-names>T.-T.</given-names></name><name><surname>Hsiao</surname><given-names>C.-W.</given-names></name><name><surname>Kou</surname><given-names>Y.-H.</given-names></name></person-group><article-title>Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>13848</fpage><lpage>13855</lpage><pub-id pub-id-type="pmid">16254320</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S.F.</given-names></name><name><surname>Quadeer</surname><given-names>A.A.</given-names></name><name><surname>McKay</surname><given-names>M.R.</given-names></name></person-group><article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies</article-title><source>Viruses</source><volume>12</volume><year>2020</year><fpage>254</fpage></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.-J.</given-names></name><name><surname>Leng</surname><given-names>C.-H.</given-names></name><name><surname>Lien</surname><given-names>S-p</given-names></name><name><surname>Chi</surname><given-names>H.-Y.</given-names></name><name><surname>Huang</surname><given-names>C.-Y.</given-names></name><name><surname>Lin</surname><given-names>C.-L.</given-names></name></person-group><article-title>Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates</article-title><source>Vaccine</source><volume>24</volume><year>2006</year><fpage>3100</fpage><lpage>3108</lpage><pub-id pub-id-type="pmid">16494977</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>X.-Y.</given-names></name><name><surname>Yuan</surname><given-names>J.-W.</given-names></name><name><surname>Vabret</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>X.-D.</given-names></name><name><surname>Yang</surname><given-names>R.-F.</given-names></name></person-group><article-title>Characterization and application of monoclonal antibodies against N protein of SARS-coronavirus</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>336</volume><year>2005</year><fpage>110</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">16112641</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>Y.-S.</given-names></name><name><surname>Lin</surname><given-names>S.-Y.</given-names></name><name><surname>Wang</surname><given-names>S.-M.</given-names></name><name><surname>Wang</surname><given-names>C.-T.</given-names></name><name><surname>Chiu</surname><given-names>Y.-L.</given-names></name><name><surname>Huang</surname><given-names>T.-H.</given-names></name></person-group><article-title>Oligomerization of the carboxyl terminal domain of the human coronavirus 229E nucleocapsid protein</article-title><source>FEBS Lett.</source><volume>587</volume><year>2013</year><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">23178926</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>I.-J.</given-names></name><name><surname>Yuann</surname><given-names>J.-M.P.</given-names></name><name><surname>Chang</surname><given-names>Y.-M.</given-names></name><name><surname>Lin</surname><given-names>S.-Y.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Crystal structure-based exploration of the important role of Arg106 in the RNA-binding domain of human coronavirus OC43 nucleocapsid protein</article-title><source>Biochim. Biophys. Acta Protein Proteonomics</source><volume>1834</volume><year>2013</year><fpage>1054</fpage><lpage>1062</lpage></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C-k</given-names></name><name><surname>Chen</surname><given-names>C.-M.M.</given-names></name><name><surname>Chiang</surname><given-names>M-h</given-names></name><name><surname>Hsu</surname><given-names>Y-l</given-names></name><name><surname>Huang</surname><given-names>T-h</given-names></name></person-group><article-title>Transient oligomerization of the SARS-CoV N protein&#x02013;implication for virus ribonucleoprotein packaging</article-title><source>PloS One</source><volume>8</volume><year>2013</year></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Saikatendu</surname><given-names>K.S.</given-names></name><name><surname>Joseph</surname><given-names>J.S.</given-names></name><name><surname>Subramanian</surname><given-names>V.</given-names></name><name><surname>Neuman</surname><given-names>B.W.</given-names></name><name><surname>Buchmeier</surname><given-names>M.J.</given-names></name><name><surname>Stevens</surname><given-names>R.C.</given-names></name></person-group><article-title>Ribonucleocapsid formation of severe acute respiratory syndrome coronavirus through molecular action of the N-terminal domain of N protein</article-title><source>J. Virol.</source><volume>81</volume><year>2007</year><fpage>3913</fpage><lpage>3921</lpage><pub-id pub-id-type="pmid">17229691</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Jayaram</surname><given-names>H.</given-names></name><name><surname>Fan</surname><given-names>H.</given-names></name><name><surname>Bowman</surname><given-names>B.R.</given-names></name><name><surname>Ooi</surname><given-names>A.</given-names></name><name><surname>Jayaram</surname><given-names>J.</given-names></name><name><surname>Collisson</surname><given-names>E.W.</given-names></name></person-group><article-title>X-ray structures of the N-and C-terminal domains of a coronavirus nucleocapsid protein: implications for nucleocapsid formation</article-title><source>J. Virol.</source><volume>80</volume><year>2006</year><fpage>6612</fpage><lpage>6620</lpage><pub-id pub-id-type="pmid">16775348</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>H.</given-names></name><name><surname>Ooi</surname><given-names>A.</given-names></name><name><surname>Tan</surname><given-names>Y.W.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Fang</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>D.X.</given-names></name></person-group><article-title>The nucleocapsid protein of coronavirus infectious bronchitis virus: crystal structure of its N-terminal domain and multimerization properties</article-title><source>Structure</source><volume>13</volume><year>2005</year><fpage>1859</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">16338414</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Grossoehme</surname><given-names>N.E.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Keane</surname><given-names>S.C.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Dann</surname><given-names>C.E.</given-names><suffix>III</suffix></name><name><surname>Leibowitz</surname><given-names>J.L.</given-names></name></person-group><article-title>Coronavirus N protein N-terminal domain (NTD) specifically binds the transcriptional regulatory sequence (TRS) and melts TRS-cTRS RNA duplexes</article-title><source>J. Mol. Biol.</source><volume>394</volume><year>2009</year><fpage>544</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">19782089</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y.W.</given-names></name><name><surname>Fang</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>H.</given-names></name><name><surname>Lescar</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name></person-group><article-title>Amino acid residues critical for RNA-binding in the N-terminal domain of the nucleocapsid protein are essential determinants for the infectivity of coronavirus in cultured cells</article-title><source>Nucleic Acids Res.</source><volume>34</volume><year>2006</year><fpage>4816</fpage><lpage>4825</lpage><pub-id pub-id-type="pmid">16971454</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Keane</surname><given-names>S.C.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Leibowitz</surname><given-names>J.L.</given-names></name><name><surname>Giedroc</surname><given-names>D.P.</given-names></name></person-group><article-title>Functional transcriptional regulatory sequence (TRS) RNA binding and helix destabilizing determinants of murine hepatitis virus (MHV) nucleocapsid (N) protein</article-title><source>J. Biol. Chem.</source><volume>287</volume><year>2012</year><fpage>7063</fpage><lpage>7073</lpage><pub-id pub-id-type="pmid">22241479</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S.-M.</given-names></name><name><surname>Lin</surname><given-names>S.-C.</given-names></name><name><surname>Hsu</surname><given-names>J.-N.</given-names></name><name><surname>Chang</surname><given-names>C-k</given-names></name><name><surname>Chien</surname><given-names>C.-M.</given-names></name><name><surname>Wang</surname><given-names>Y.-S.</given-names></name></person-group><article-title>Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design</article-title><source>J. Med. Chem.</source><volume>63</volume><issue>6</issue><year>2020</year><fpage>3131</fpage><lpage>3141</lpage><pub-id pub-id-type="pmid">32105468</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Hong</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites</article-title><source>Acta Pharmaceutica Sinica B</source><year>2020</year><comment>In press</comment></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Chazal</surname><given-names>N.</given-names></name><name><surname>Gerlier</surname><given-names>D.</given-names></name></person-group><article-title>Virus entry, assembly, budding, and membrane rafts</article-title><source>Microbiol. Mol. Biol. Rev.</source><volume>67</volume><year>2003</year><fpage>226</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">12794191</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zuo</surname><given-names>W.</given-names></name></person-group><article-title>Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov</article-title><source>BioRxiv</source><year>2020</year><comment>In press</comment></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Ke</surname><given-names>A.</given-names></name></person-group><article-title>Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection</article-title><source>bioRxiv</source><year>2020</year><comment>Preprint</comment></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>Z.</given-names></name><name><surname>Gong</surname><given-names>H.</given-names></name></person-group><article-title>Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process</article-title><source>Gut</source><year>2020</year><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320953</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>K.</given-names></name><name><surname>Zou</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>Z.</given-names></name></person-group><article-title>Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection</article-title><source>Front. Med.</source><year>2020</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">31823287</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Cai</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>B.</given-names></name><name><surname>Tan</surname><given-names>Z.</given-names></name></person-group><article-title>Cell membrane proteins with high n-glycosylation, high expression and multiple interaction partners are preferred by mammalian viruses as receptors</article-title><source>Bioinformatics</source><volume>35</volume><year>2019</year><fpage>723</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">30102334</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Mueller</surname><given-names>M.A.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S.</given-names></name></person-group><article-title>The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells</article-title><source>BioRxiv</source><year>2020</year><comment>Preprint</comment></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name></person-group><article-title>Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2</article-title><source>Virus Res.</source><volume>136</volume><year>2008</year><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">18554741</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools</article-title><source>Virol. Sin.</source><year>2020</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">31916022</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Qian</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>526</volume><issue>1</issue><year>2020</year><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">32199615</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Gramberg</surname><given-names>T.</given-names></name><name><surname>Simmons</surname><given-names>G.</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>P.</given-names></name><name><surname>Rennekamp</surname><given-names>A.J.</given-names></name><name><surname>Krumbiegel</surname><given-names>M.</given-names></name></person-group><article-title>DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><volume>78</volume><year>2004</year><fpage>12090</fpage><lpage>12095</lpage><pub-id pub-id-type="pmid">15479853</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Peck</surname><given-names>K.M.</given-names></name><name><surname>Scobey</surname><given-names>T.</given-names></name><name><surname>Swanstrom</surname><given-names>J.</given-names></name><name><surname>Jensen</surname><given-names>K.L.</given-names></name><name><surname>Burch</surname><given-names>C.L.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Permissivity of dipeptidyl peptidase 4 orthologs to Middle East respiratory syndrome coronavirus is governed by glycosylation and other complex determinants</article-title><source>J. Virol.</source><volume>91</volume><year>2017</year><comment>e00534-17</comment></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor recognition mechanisms of coronaviruses: a decade of structural studies</article-title><source>J. Virol.</source><volume>89</volume><year>2015</year><fpage>1954</fpage><lpage>1964</lpage><pub-id pub-id-type="pmid">25428871</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus&#x02013;infected pneumonia</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Semba</surname><given-names>R.D.</given-names></name></person-group><article-title>Vitamin A and immunity to viral, bacterial and protozoan infections</article-title><source>Proc. Nutr. Soc.</source><volume>58</volume><year>1999</year><fpage>719</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">10604208</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Keil</surname><given-names>S.D.</given-names></name><name><surname>Bowen</surname><given-names>R.</given-names></name><name><surname>Marschner</surname><given-names>S.</given-names></name></person-group><article-title>Inactivation of M iddle E ast respiratory syndrome coronavirus (MERS&#x02010;C o V) in plasma products using a riboflavin&#x02010;based and ultraviolet light&#x02010;based photochemical treatment</article-title><source>Transfusion</source><volume>56</volume><year>2016</year><fpage>2948</fpage><lpage>2952</lpage><pub-id pub-id-type="pmid">27805261</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Atherton</surname><given-names>J.</given-names></name><name><surname>Kratzing</surname><given-names>C.</given-names></name><name><surname>Fisher</surname><given-names>A.</given-names></name></person-group><article-title>The effect of ascorbic acid on infection of chick-embryo ciliated tracheal organ cultures by coronavirus</article-title><source>Arch. Virol.</source><volume>56</volume><year>1978</year><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">205194</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Nonnecke</surname><given-names>B.</given-names></name><name><surname>McGill</surname><given-names>J.</given-names></name><name><surname>Ridpath</surname><given-names>J.</given-names></name><name><surname>Sacco</surname><given-names>R.</given-names></name><name><surname>Lippolis</surname><given-names>J.</given-names></name><name><surname>Reinhardt</surname><given-names>T.</given-names></name></person-group><article-title>Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves</article-title><source>J. Dairy Sci.</source><volume>97</volume><year>2014</year><fpage>5566</fpage><lpage>5579</lpage><pub-id pub-id-type="pmid">25022687</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>M.A.</given-names></name><name><surname>Kolbeck</surname><given-names>P.C.</given-names></name><name><surname>Rohr</surname><given-names>L.H.</given-names></name><name><surname>Shi</surname><given-names>Q.</given-names></name><name><surname>Morris</surname><given-names>V.C.</given-names></name><name><surname>Levander</surname><given-names>O.A.</given-names></name></person-group><article-title>Vitamin E deficiency intensifies the myocardial injury of coxsackievirus B3 infection of mice</article-title><source>J. Nutr.</source><volume>124</volume><year>1994</year><fpage>345</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">8120653</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>M.</given-names></name><name><surname>Kuba</surname><given-names>K.</given-names></name><name><surname>Ichikawa</surname><given-names>A.</given-names></name><name><surname>Nakayama</surname><given-names>M.</given-names></name><name><surname>Katahira</surname><given-names>J.</given-names></name><name><surname>Iwamoto</surname><given-names>R.</given-names></name></person-group><article-title>The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza</article-title><source>Cell</source><volume>153</volume><year>2013</year><fpage>112</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">23477864</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Rayman</surname><given-names>M.P.</given-names></name></person-group><article-title>Selenium and human health</article-title><source>Lancet</source><volume>379</volume><year>2012</year><fpage>1256</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">22381456</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Te Velthuis</surname><given-names>A.J.</given-names></name><name><surname>van den Worm</surname><given-names>S.H.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>van Hemert</surname><given-names>M.J.</given-names></name></person-group><article-title>Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture</article-title><source>PLoS Pathog.</source><volume>6</volume><year>2010</year></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Wessling-Resnick</surname><given-names>M.</given-names></name></person-group><article-title>Crossing the iron gate: why and how transferrin receptors mediate viral entry</article-title><source>Annu. Rev. Nutr.</source><volume>38</volume><year>2018</year><fpage>431</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">29852086</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Momattin</surname><given-names>H.</given-names></name><name><surname>Al-Ali</surname><given-names>A.Y.</given-names></name><name><surname>Mohammed</surname><given-names>K.</given-names></name><name><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name></person-group><article-title>Benchmarking of antibiotic usage: an adjustment to reflect antibiotic stewardship program outcome in a hospital in Saudi Arabia</article-title><source>J. Infect. Publ. Health</source><volume>11</volume><year>2018</year><fpage>310</fpage><lpage>313</lpage></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>T.W.</given-names></name><name><surname>Kwek</surname><given-names>T.-K.</given-names></name><name><surname>Tai</surname><given-names>D.</given-names></name><name><surname>Earnest</surname><given-names>A.</given-names></name><name><surname>Loo</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name></person-group><article-title>Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome</article-title><source>JAMA</source><volume>290</volume><year>2003</year><fpage>374</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">12865379</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>C.A.</given-names></name><name><surname>Badamchian</surname><given-names>M.</given-names></name><name><surname>Goldstein</surname><given-names>A.L.</given-names></name></person-group><article-title>Thymosin &#x003b1;1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways</article-title><source>Mech. Ageing Dev.</source><volume>94</volume><year>1997</year><fpage>85</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">9147362</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome. Protection and disinfection policies against SARS-CoV-2 (COVID-19)</article-title><source>Chin. Crit. Care Med.</source><volume>15</volume><year>2003</year><fpage>332</fpage><lpage>335</lpage></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Jung</surname><given-names>Y.-S.</given-names></name><name><surname>Liang</surname><given-names>P.-H.</given-names></name></person-group><article-title>Anti-SARS coronavirus agents: a patent review (2008&#x02013;present)</article-title><source>Expert Opin. Ther. Pat.</source><volume>23</volume><year>2013</year><fpage>1337</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">23905913</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Duchateau</surname><given-names>J.</given-names></name><name><surname>Servais</surname><given-names>G.</given-names></name><name><surname>Vreyens</surname><given-names>R.</given-names></name><name><surname>Delespesse</surname><given-names>G.</given-names></name><name><surname>Bolla</surname><given-names>K.</given-names></name></person-group><article-title>Modulation of immune response in aged humans through different administration modes of thymopentin</article-title><source>Surv. Immunol. Res.</source><volume>4</volume><year>1985</year><fpage>94</fpage><pub-id pub-id-type="pmid">3898299</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Joffe</surname><given-names>M.</given-names></name><name><surname>Sukha</surname><given-names>N.</given-names></name><name><surname>Rabson</surname><given-names>A.</given-names></name></person-group><article-title>Lymphocyte subsets in measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid</article-title><source>J. Clin. Invest.</source><volume>72</volume><year>1983</year><fpage>971</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">6604071</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Gui</surname><given-names>C.</given-names></name><name><surname>Yue</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>C.</given-names></name></person-group><article-title>Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>321</volume><year>2004</year><fpage>557</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">15358143</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.-Y.</given-names></name><name><surname>Jeong</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>Y.M.</given-names></name><name><surname>Park</surname><given-names>S.-J.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name></person-group><article-title>Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus</article-title><source>Biol. Pharm. Bull.</source><volume>35</volume><issue>11</issue><year>2012</year><fpage>2036</fpage><lpage>2042</lpage><pub-id pub-id-type="pmid">22971649</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gui</surname><given-names>C.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name><name><surname>Scandella</surname><given-names>E.</given-names></name></person-group><article-title>Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>7095</fpage><lpage>7103</lpage><pub-id pub-id-type="pmid">15890949</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Diwan</surname><given-names>A.</given-names></name><name><surname>Ninawe</surname><given-names>A.</given-names></name><name><surname>Harke</surname><given-names>S.</given-names></name></person-group><article-title>Gene editing (CRISPR-Cas) technology and fisheries sector</article-title><source>Can. J. Biotechnol.</source><volume>1</volume><year>2017</year><fpage>65</fpage><lpage>72</lpage></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name></person-group><article-title>Characteristics of flavonoids as potent MERS&#x02010;CoV 3C&#x02010;like protease inhibitors</article-title><source>Chem. Biol. Drug Des.</source><volume>94</volume><year>2019</year><fpage>2023</fpage><lpage>2030</lpage><pub-id pub-id-type="pmid">31436895</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Berne</surname><given-names>M.A.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Dimitrov</surname><given-names>D.S.</given-names></name></person-group><article-title>The secret life of ACE2 as a receptor for the SARS virus</article-title><source>Cell</source><volume>115</volume><year>2003</year><fpage>652</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">14675530</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Potential interventions for novel coronavirus in China: a systematic review</article-title><source>J. Med. Virol.</source><volume>92</volume><issue>5</issue><year>2020</year><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">32052466</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>K.S.</given-names></name><name><surname>Yamanaka</surname><given-names>G.A.</given-names></name><name><surname>Meanwell</surname><given-names>N.A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus entry into host cells: opportunities for therapeutic intervention</article-title><source>Med. Res. Rev.</source><volume>26</volume><year>2006</year><fpage>414</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">16521129</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Murakami</surname><given-names>A.</given-names></name><name><surname>Tamin</surname><given-names>A.</given-names></name><name><surname>Matthews</surname><given-names>L.J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name></person-group><article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title><source>Proc. Natl. Acad. Sci. Unit. States Am.</source><volume>101</volume><year>2004</year><fpage>2536</fpage><lpage>2541</lpage></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Boelaert</surname><given-names>J.R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name><name><surname>Majori</surname><given-names>G.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name></person-group><article-title>Effects of chloroquine on viral infections: an old drug against today's diseases</article-title><source>Lancet Infect. Dis.</source><volume>3</volume><year>2003</year><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">14592603</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name><surname>Alves</surname><given-names>D.S.</given-names></name><name><surname>P&#x000e9;rez-Fons</surname><given-names>L.</given-names></name><name><surname>Estepa</surname><given-names>A.</given-names></name><name><surname>Micol</surname><given-names>V.</given-names></name></person-group><article-title>Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin</article-title><source>Biochem. Pharmacol.</source><volume>68</volume><year>2004</year><fpage>549</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">15242821</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name><surname>Vickers</surname><given-names>N.J.</given-names></name></person-group><article-title>Animal communication: when I'm calling you, will you answer too?</article-title><source>Curr. Biol.</source><volume>27</volume><year>2017</year><fpage>R713</fpage><lpage>R715</lpage><pub-id pub-id-type="pmid">28743020</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.W.</given-names></name><name><surname>Yap</surname><given-names>Y.L.</given-names></name></person-group><article-title>Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs</article-title><source>Bioorg. Med. Chem.</source><volume>12</volume><year>2004</year><fpage>2517</fpage><lpage>2521</lpage><pub-id pub-id-type="pmid">15110833</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name><surname>Cauwenberghs</surname><given-names>S.</given-names></name><name><surname>Feijge</surname><given-names>M.A.</given-names></name><name><surname>Harper</surname><given-names>A.G.</given-names></name><name><surname>Sage</surname><given-names>S.O.</given-names></name><name><surname>Curvers</surname><given-names>J.</given-names></name><name><surname>Heemskerk</surname><given-names>J.W.</given-names></name></person-group><article-title>Shedding of procoagulant microparticles from unstimulated platelets by integrin&#x02010;mediated destabilization of actin cytoskeleton</article-title><source>FEBS Lett.</source><volume>580</volume><year>2006</year><fpage>5313</fpage><lpage>5320</lpage><pub-id pub-id-type="pmid">16979629</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Yoshiya</surname><given-names>T.</given-names></name><name><surname>Yoshizawa-Kumagaye</surname><given-names>K.</given-names></name><name><surname>Sugiyama</surname><given-names>T.</given-names></name></person-group><article-title>Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean</article-title><source>Biomed. Res.</source><volume>36</volume><year>2015</year><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">26106051</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name><surname>Ksiazek</surname><given-names>T.G.</given-names></name><name><surname>Erdman</surname><given-names>D.</given-names></name><name><surname>Goldsmith</surname><given-names>C.S.</given-names></name><name><surname>Zaki</surname><given-names>S.R.</given-names></name><name><surname>Peret</surname><given-names>T.</given-names></name><name><surname>Emery</surname><given-names>S.</given-names></name></person-group><article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title><source>N. Engl. J. Med.</source><volume>348</volume><year>2003</year><fpage>1953</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">12690092</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name><surname>Morgenstern</surname><given-names>B.</given-names></name><name><surname>Michaelis</surname><given-names>M.</given-names></name><name><surname>Baer</surname><given-names>P.C.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Ribavirin and interferon-&#x003b2; synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>326</volume><year>2005</year><fpage>905</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">15607755</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>K.</given-names></name><name><surname>Zhong</surname><given-names>N.S.</given-names></name></person-group><article-title>SARS: pharmacotherapy</article-title><source>Respirology</source><volume>8</volume><year>2003</year><fpage>S25</fpage><lpage>S30</lpage><pub-id pub-id-type="pmid">15018130</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>U.J.</given-names></name><name><surname>Won</surname><given-names>E.-J.</given-names></name><name><surname>Kee</surname><given-names>S.-J.</given-names></name><name><surname>Jung</surname><given-names>S.-I.</given-names></name><name><surname>Jang</surname><given-names>H.-C.</given-names></name></person-group><article-title>Case report Combination therapy with lopinavir/ritonavir, ribavirin and interferon-&#x003b1; for Middle East respiratory syndrome</article-title><source>Antivir. Ther.</source><volume>21</volume><year>2016</year><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">26492219</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>M.L.</given-names></name><name><surname>Andres</surname><given-names>E.L.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group><article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title><source>mBio</source><volume>9</volume><year>2018</year><comment>e00221-18</comment></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Won</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">31911652</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Yoshinaka</surname><given-names>Y.</given-names></name><name><surname>Amari</surname><given-names>S.</given-names></name><name><surname>Nakano</surname><given-names>T.</given-names></name><name><surname>Cinatl</surname><given-names>J.</given-names></name></person-group><article-title>HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>318</volume><year>2004</year><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="pmid">15144898</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name><surname>Khamitov</surname><given-names>R.</given-names></name><name><surname>Loginova</surname><given-names>S.</given-names></name><name><surname>Shchukina</surname><given-names>V.</given-names></name><name><surname>Borisevich</surname><given-names>S.</given-names></name><name><surname>Maksimov</surname><given-names>V.</given-names></name><name><surname>Shuster</surname><given-names>A.</given-names></name></person-group><article-title>Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures</article-title><source>Vopr. Virusol.</source><volume>53</volume><year>2008</year><fpage>9</fpage><lpage>13</lpage></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>R.A.</given-names></name><name><surname>Grisham</surname><given-names>M.B.</given-names></name></person-group><article-title>Nitric oxide</article-title><source>Int. J. Biochem. Cell Biol.</source><volume>29</volume><year>1997</year><fpage>857</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">9304799</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name><surname>&#x000c5;kerstr&#x000f6;m</surname><given-names>S.</given-names></name><name><surname>Mousavi-Jazi</surname><given-names>M.</given-names></name><name><surname>Klingstr&#x000f6;m</surname><given-names>J.</given-names></name><name><surname>Leijon</surname><given-names>M.</given-names></name><name><surname>&#x000c5;</surname><given-names>Lundkvist</given-names></name><name><surname>Mirazimi</surname><given-names>A.</given-names></name></person-group><article-title>Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>1966</fpage><lpage>1969</lpage><pub-id pub-id-type="pmid">15650225</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="book" id="sref120"><person-group person-group-type="author"><name><surname>Talluri</surname><given-names>S.</given-names></name></person-group><chapter-title>Virtual High Throughput Screening Based Prediction of Potential Drugs for COVID-19</chapter-title><year>2020</year></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name><surname>Macalino</surname><given-names>S.J.Y.</given-names></name><name><surname>Gosu</surname><given-names>V.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Role of computer-aided drug design in modern drug discovery</article-title><source>Arch Pharm. Res. (Seoul)</source><volume>38</volume><year>2015</year><fpage>1686</fpage><lpage>1701</lpage></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name><surname>Mohanasundaram</surname><given-names>N.</given-names></name><name><surname>Sekhar</surname><given-names>T.</given-names></name></person-group><article-title>Computational studies of molecular targets regarding the adverse effects of isoniazid drug for tuberculosis</article-title><source>Curr. Pharmacogenom. Pers. Med. (Former. Curr. Pharmacogenom.)</source><volume>16</volume><year>2018</year><fpage>210</fpage><lpage>218</lpage></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Butte</surname><given-names>A.J.</given-names></name><name><surname>Swamidass</surname><given-names>S.J.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name></person-group><article-title>A survey of current trends in computational drug repositioning</article-title><source>Bioinf.</source><volume>17</volume><year>2016</year><fpage>2</fpage><lpage>12</lpage></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name><surname>Hurle</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>Q.</given-names></name><name><surname>Rajpal</surname><given-names>D.</given-names></name><name><surname>Sanseau</surname><given-names>P.</given-names></name><name><surname>Agarwal</surname><given-names>P.</given-names></name></person-group><article-title>Computational drug repositioning: from data to therapeutics</article-title><source>Clin. Pharmacol. Therapeut.</source><volume>93</volume><year>2013</year><fpage>335</fpage><lpage>341</lpage></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name><surname>Novac</surname><given-names>N.</given-names></name></person-group><article-title>Challenges and opportunities of drug repositioning</article-title><source>Trends Pharmacol. Sci.</source><volume>34</volume><year>2013</year><fpage>267</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">23582281</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="book" id="sref126"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Rao</surname><given-names>Z.</given-names></name></person-group><chapter-title>The Crystal Structure of 2019-NCoV Main Protease in Complex with an Inhibitor N3</chapter-title><year>2020</year><publisher-name>RCSB Protein Data Bank</publisher-name></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source>J. Med. Virol.</source><volume>92</volume><issue>4</issue><year>2020</year><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A.</given-names></name><name><surname>Lombardo</surname><given-names>F.</given-names></name><name><surname>Dominy</surname><given-names>B.W.</given-names></name><name><surname>Feeney</surname><given-names>P.J.</given-names></name></person-group><article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title><source>Adv. Drug Deliv. Rev.</source><volume>23</volume><year>1997</year><fpage>3</fpage><lpage>25</lpage></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>J.P.</given-names></name><name><surname>Rees</surname><given-names>S.</given-names></name><name><surname>Kalindjian</surname><given-names>S.B.</given-names></name><name><surname>Philpott</surname><given-names>K.L.</given-names></name></person-group><article-title>Principles of early drug discovery</article-title><source>Br. J. Pharmacol.</source><volume>162</volume><year>2011</year><fpage>1239</fpage><lpage>1249</lpage><pub-id pub-id-type="pmid">21091654</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.-J.</given-names></name><name><surname>Yu</surname><given-names>H.W.</given-names></name><name><surname>Chen</surname><given-names>C.-Y.</given-names></name><name><surname>Hsu</surname><given-names>C.-H.</given-names></name><name><surname>Chen</surname><given-names>H.-Y.</given-names></name><name><surname>Lee</surname><given-names>K.-J.</given-names></name></person-group><article-title>Current developments of computer-aided drug design</article-title><source>J. Taiwan Inst. Chem. Eng.</source><volume>41</volume><year>2010</year><fpage>623</fpage><lpage>635</lpage></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name><surname>Kapetanovic</surname><given-names>I.</given-names></name></person-group><article-title>Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach</article-title><source>Chem. Biol. Interact.</source><volume>171</volume><year>2008</year><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">17229415</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group><article-title>Computational identification and binding analysis of orphan human cytochrome P450 4X1 enzyme with substrates</article-title><source>BMC Res. Notes</source><volume>8</volume><year>2015</year><fpage>9</fpage><pub-id pub-id-type="pmid">25595103</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name><surname>Van Drie</surname><given-names>J.H.</given-names></name></person-group><article-title>Computer-aided drug design: the next 20 years</article-title><source>J. Comput. Aided Mol. Des.</source><volume>21</volume><year>2007</year><fpage>591</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">17989929</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name><surname>Veselovsky</surname><given-names>A.</given-names></name><name><surname>Ivanov</surname><given-names>A.</given-names></name></person-group><article-title>Strategy of computer-aided drug design</article-title><source>Curr. Drug Targets - Infect. Disord.</source><volume>3</volume><year>2003</year><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12570731</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name><surname>Coordinators</surname><given-names>N.R.</given-names></name></person-group><article-title>Database resources of the national center for biotechnology information</article-title><source>Nucleic Acids Res.</source><volume>45</volume><year>2017</year><fpage>D12</fpage><lpage>D17</lpage><pub-id pub-id-type="pmid">27899561</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name><surname>Marchler-Bauer</surname><given-names>A.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Anderson</surname><given-names>J.</given-names></name><name><surname>Chitsaz</surname><given-names>F.</given-names></name><name><surname>Derbyshire</surname><given-names>M.</given-names></name><name><surname>DeWeese-Scott</surname><given-names>C.</given-names></name></person-group><article-title>CDD: a Conserved Domain Database for the functional annotation of proteins</article-title><source>Nucleic Acids Res.</source><volume>39</volume><year>2011</year><fpage>D225</fpage><lpage>D229</lpage><pub-id pub-id-type="pmid">21109532</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>K.-C.</given-names></name><name><surname>Shen</surname><given-names>H.-B.</given-names></name></person-group><article-title>Cell-PLoc 2.0: an improved package of web-servers for predicting subcellular localization of proteins in various organisms</article-title><source>Nat. Sci.</source><volume>2</volume><year>2010</year><fpage>1090</fpage></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>L.</given-names></name><name><surname>Mezulis</surname><given-names>S.</given-names></name><name><surname>Yates</surname><given-names>C.</given-names></name><name><surname>Wass</surname><given-names>M.</given-names></name><name><surname>Sternberg</surname><given-names>M.</given-names></name></person-group><article-title>The Phyre2 web portal for protein modeling, prediction and analysis</article-title><source>Nat. Protoc.</source><volume>10</volume><year>2015</year><fpage>845</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">25950237</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="book" id="sref139"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name></person-group><chapter-title>Drug and Vaccine Design against Novel Coronavirus (2019-nCoV) Spike Protein through Computational Approach</chapter-title><year>2020</year></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name><surname>Lindenbach</surname><given-names>B.D.</given-names></name><name><surname>Rice</surname><given-names>C.M.</given-names></name></person-group><article-title>Molecular biology of flaviviruses</article-title><source>Adv. Virus Res.</source><volume>59</volume><year>2003</year><fpage>23</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14696326</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>B.J.</given-names></name><name><surname>van der Zee</surname><given-names>R.</given-names></name><name><surname>de Haan</surname><given-names>C.A.</given-names></name><name><surname>Rottier</surname><given-names>P.J.</given-names></name></person-group><article-title>The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex</article-title><source>J. Virol.</source><volume>77</volume><year>2003</year><fpage>8801</fpage><lpage>8811</lpage><pub-id pub-id-type="pmid">12885899</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Annu. Rev. Virol.</source><volume>3</volume><year>2016</year><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">27578435</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Snijder</surname><given-names>J.</given-names></name><name><surname>Xiong</surname><given-names>X.</given-names></name><name><surname>Bosch</surname><given-names>B.-J.</given-names></name><name><surname>Rey</surname><given-names>F.A.</given-names></name></person-group><article-title>Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion</article-title><source>Proc. Natl. Acad. Sci. Unit. States Am.</source><volume>114</volume><year>2017</year><fpage>11157</fpage><lpage>11162</lpage></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name><surname>ul Qamar</surname><given-names>M.T.</given-names></name><name><surname>Bari</surname><given-names>A.</given-names></name><name><surname>Adeel</surname><given-names>M.M.</given-names></name><name><surname>Maryam</surname><given-names>A.</given-names></name><name><surname>Ashfaq</surname><given-names>U.A.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name></person-group><article-title>Peptide vaccine against chikungunya virus: immuno-informatics combined with molecular docking approach</article-title><source>J. Transl. Med.</source><volume>16</volume><year>2018</year><fpage>298</fpage><pub-id pub-id-type="pmid">30368237</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2</article-title><source>BioRxiv</source><year>2020</year><comment>Preprint</comment></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgment</title><p>We thank all staff of Imam Reza Hospital for all they did during Covid-19 pandemic and in memorial of all our colleagues lost their life during this pandemic.</p></ack></back></article>